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A B S T R A C T
Background
Electronic cigarettes (ECs) are electronic devices that heat a liquid into an aerosol for inhalation. The liquid usually comprises propylene
glycol and glycerol, with or without nicotine and flavours, and stored in disposable or refillable cartridges or a reservoir. Since ECs
appeared on the market in 2006 there has been a steady growth in sales. Smokers report using ECs to reduce risks of smoking, but some
healthcare organizations, tobacco control advocacy groups and policy makers have been reluctant to encourage smokers to switch to
ECs, citing lack of evidence of efficacy and safety. Smokers, healthcare providers and regulators are interested to know if these devices
can help smokers quit and if they are safe to use for this purpose. This review is an update of a review first published in 2014.
Objectives
To evaluate the safety and effect of using ECs to help people who smoke achieve long-term smoking abstinence.
Search methods
We searched the Cochrane Tobacco Addiction Group’s Specialized Register, the Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, Embase, and PsycINFO for relevant records from 2004 to January 2016, together with reference checking and
contact with study authors.
Selection criteria
We included randomized controlled trials (RCTs) in which current smokers (motivated or unmotivated to quit) were randomized to
EC or a control condition, and which measured abstinence rates at six months or longer. As the field of EC research is new, we also
included cohort follow-up studies with at least six months follow-up. We included randomized cross-over trials, RCTs and cohort
follow-up studies that included at least one week of EC use for assessment of adverse events (AEs).
Data collection and analysis
We followed standard Cochrane methods for screening and data extraction. Our main outcome measure was abstinence from smoking
after at least six months follow-up, and we used the most rigorous definition available (continuous, biochemically validated, longest
follow-up). We used a fixed-effect Mantel-Haenszel model to calculate the risk ratio (RR) with a 95% confidence interval (CI) for each
study, and where appropriate we pooled data from these studies in meta-analyses.
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Main results
Our searches identified over 1700 records, from which we include 24 completed studies (three RCTs, two of which were eligible for
our cessation meta-analysis, and 21 cohort studies). Eleven of these studies are new for this version of the review. We identified 27
ongoing studies. Two RCTs compared EC with placebo (non-nicotine) EC, with a combined sample size of 662 participants. One
trial included minimal telephone support and one recruited smokers not intending to quit, and both used early EC models with low
nicotine content and poor battery life. We judged the RCTs to be at low risk of bias, but under the GRADE system we rated the overall
quality of the evidence for our outcomes as ‘low’ or ‘very low’, because of imprecision due to the small number of trials. A ‘low’ grade
means that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change
the estimate. A ‘very low’ grade means we are very uncertain about the estimate. Participants using an EC were more likely to have
abstained from smoking for at least six months compared with participants using placebo EC (RR 2.29, 95% CI 1.05 to 4.96; placebo
4% versus EC 9%; 2 studies; 662 participants. GRADE: low). The one study that compared EC to nicotine patch found no significant
difference in six-month abstinence rates, but the confidence intervals do not rule out a clinically important difference (RR 1.26, 95%
CI 0.68 to 2.34; 584 participants. GRADE: very low).
Of the included studies, none reported serious adverse events considered related toECuse. Themost frequently reportedAEsweremouth
and throat irritation, most commonly dissipating over time. One RCT provided data on the proportion of participants experiencing
any adverse events. The proportion of participants in the study arms experiencing adverse events was similar (ECs vs placebo EC: RR
0.97, 95% CI 0.71 to 1.34 (298 participants); ECs vs patch: RR 0.99, 95% CI 0.81 to 1.22 (456 participants)). The second RCT
reported no statistically significant difference in the frequency of AEs at three- or 12-month follow-up between the EC and placebo EC
groups, and showed that in all groups the frequency of AEs (with the exception of throat irritation) decreased significantly over time.
Authors’ conclusions
There is evidence from two trials that ECs help smokers to stop smoking in the long term compared with placebo ECs. However, the
small number of trials, low event rates and wide confidence intervals around the estimates mean that our confidence in the result is
rated ’low’ by GRADE standards. The lack of difference between the effect of ECs compared with nicotine patches found in one trial
is uncertain for similar reasons. None of the included studies (short- to mid-term, up to two years) detected serious adverse events
considered possibly related to EC use. The most commonly reported adverse effects were irritation of the mouth and throat. The long-
term safety of ECs is unknown. In this update, we found a further 15 ongoing RCTs which appear eligible for this review.
P L A I N L A N G U A G E S U M M A R Y
Can electronic cigarettes help people stop smoking, and are they safe to use for this purpose?
Background
Electronic cigarettes (ECs) are electronic devices that produce an aerosol (commonly referred to as vapour) that the user inhales. This
vapour typically contains nicotine without most of the toxins smokers inhale with cigarette smoke. ECs have become popular with
smokers who want to reduce the risks of smoking. This review aimed to find out whether ECs help smokers stop smoking, and whether
it is safe to use ECs to do this.
Study characteristics
This is an update of a previous review. The first review was published in 2014 and included 13 studies. For this update, we searched
for studies published up to January 2016 and found 11 new studies. Only two of the included studies are randomized controlled trials
and followed participants for at least six months. These provide the best evidence. The remaining 22 studies either did not follow
participants for very long or did not put people into treatment groups so could not directly compare ECs with something else. These
studies can tell us less about how ECs might help with quitting smoking but can tell us about short-term safety. The two randomized
trials, conducted in New Zealand and Italy, compared ECs with and without nicotine. We judged these studies to be at low risk of bias.
In one study, people wanted to quit smoking, while in the other study they did not. The trial in people who wanted to quit smoking
also compared ECs to nicotine patches.
Key results
Combined results from two studies, involving 662 people, showed that using an EC containing nicotine increased the chances of
stopping smoking in the long term compared to using an ECwithout nicotine. We could not determine if EC was better than a nicotine
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patch in helping people stop smoking, because the number of participants in the study was low. More studies are needed to evaluate
this effect. The other studies were of lower quality, but they supported these findings. None of the studies found that smokers who
used EC short- to mid-term (for two years or less) had an increased health risk compared to smokers who did not use ECs.
Quality of the evidence
The quality of the evidence overall is low because it is based on only a small number of studies, although these studies were well
conducted. More studies of ECs are needed. Some are already underway.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Electronic cigarettes (EC) for smoking cessation
Patient or population: people def ined as current smokers at enrolment into trials, motivated or unmotivated to quit
Intervention: nicot ine-containing electronic cigarettes
Comparison: placebo electronic cigarettes or nicot ine replacement therapy (or for adverse events, uncontrolled)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk1 Corresponding risk
Control Electronic cigarettes
Cessation: Nicotine EC
versus placebo EC2
assessed with exhaled
CO
Follow-up: 6 - 12
months
40 per 1000 93 per 1000
(42 to 201)
RR 2.29
(1.05 to 4.96)
662
(2 studies)
⊕⊕©©
low3,4
Only RCTs reported
here. Some cohort data
also available (see full
review) but only RCTs
provide ef f icacy data
Cessation: Nicotine EC
versus nicotine re-
placement therapy
assessed with exhaled
CO
Follow-up: 6 months
58 per 1000 73 per 1000
(39 to 135)
RR 1.26
(0.68 to 2.34)
584
(1 study)
⊕©©©
very low3,5
As above
Adverse events (AEs)
Follow-up: 6 - 24
months
Summary data not available. No studies reported serious AEs considered
related to EC use. One RCT provided data on the proport ion of part icipants
experiencing any adverse events. The proport ion of part icipants in the
study arms experiencing adverse events was sim ilar (ECs vs placebo EC:
RR 0.97, 95% CI 0.71 to 1.34 (298 part icipants); ECs vs patch: RR 0.99,
95% CI 0.81 to 1.22 (456 part icipants)). The second RCT reported no
stat ist ically signif icant dif f erence in the f requency of AEs at three- or 12-
month follow-up between the EC and placebo EC groups. Cohort studies
found mouth and throat irritat ion, dissipat ing over t ime, to be the most
1201
(11 studies (2 RCTs, 9
cohort))
⊕⊕©©
low6,7
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f requent ly reported AEs in EC users
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1’Assumed risk’ calculated as risk in control groups.
2’Placebo EC’ refers to ECs which do not contain nicot ine.
3Downgraded one level due to indirectness. The electronic cigarette used in Bullen 2013 was not very ef fect ive at delivering
nicot ine.
4Downgraded one level due to imprecision. Only two included studies, small number of events (< 300) in each arm.
5Downgraded two levels due to imprecision. Only one included study, with small number of events in each arm.
6Downgraded due to risk of bias. 11/ 13 included studies (cohort studies) judged to be at high risk of bias.
7Downgraded due to imprecision. Only one trial provided data for nicot ine EC versus nicot ine replacement therapy
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B A C K G R O U N D
Throughout this review, we discuss two types of cigarettes: elec-
tronic and conventional tobacco cigarettes. To avoid confusion,
all mention of smoking, smoking cessation, cigarette use, smoke
intake, etc., concern conventional cigarettes. When the text con-
cerns electronic cigarettes we use the abbreviation ’ECs’. EC users
are sometimes described as vapers, and EC use as vaping. We refer
to ECs that do not contain nicotine as placebo ECs.
Description of the condition
Stopping smoking is associated with large health benefits. Despite
most smokers wanting to quit, many find it difficult to succeed in
the long term. Almost half who try to quit without support will
not manage to stop for even a week, and fewer than five per cent
remain abstinent at one year after quitting (Hughes 2004).
Behavioural support and medications such as nicotine patches or
gum increase the chances of quitting, but evenwith this additional
support long-term quit rates remain low (Cahill 2016; Hughes
2014; Lancaster 2005; Stead 2005; Stead 2006; Stead 2012). One
of the limitations of current treatments is that none adequately
addresses the sensory and behavioural aspects of smoking that
smokers miss when they stop smoking (e.g. holding a cigarette in
their hands, taking a puff, enjoyment of smoking, etc.). ECs may
offer a way to overcome this limitation.
There is no doubt that people become dependent on tobacco, and
find it difficult to stop smoking, primarily because of nicotine and
its actions on the brain’s reward system (Balfour 2004). However,
other factors also contribute to tobacco dependence (Rose 2006).
Sensory and behavioural cues provide additional reinforcement of
smoking behaviour (Rose 1993; Rose 2000) and over time be-
come almost as rewarding as nicotine. There are several lines of
evidence to support this. Firstly, smokers appear to have a pref-
erence for cigarette smoke compared to other forms of nicotine
delivery. This is partly related to its speed of nicotine delivery.
However, evenwhen nicotine is administered intravenously it does
not provide the same level of satisfaction or reward as smoking
(Rose 2000; Westman 1996). Secondly, the local sensory effects
of smoking (e.g. the ‘scratch’ in the back of the throat) may be
important for enjoyment and reward. Numbing the sensations of
cigarette smoke by anaesthetizing the upper and lower respiratory
tract leads to less enjoyment of smoking (Rose 1985). Conversely,
products that mimic the sensory effects of smoking on the mouth
and throat (such as citric acid, black pepper, and ascorbic acid)
reduce craving and some withdrawal symptoms, at least in the
short term (Levin 1993; Rose 1994; Westman 1995). Thirdly,
de-nicotinized cigarettes (DNCs), which have a very low content
of nicotine (e.g. 0.08 mg instead of the normal 1 mg) and so have
negligible or no central effects, have also been investigated for
their role in aiding smoking cessation (Przulj 2013). Despite not
delivering nicotine, DNCs are satisfying over the initial few days
of abstinence from nicotine (Donny 2007; Pickworth 1999; Rose
2000). They also reduce tobacco withdrawal symptoms, includ-
ing urges to smoke and low mood (Barrett 2010; Donny 2009;
McRobbie 2016; Perkins 2010; Rose 2000), and have been shown
to improve long-term continuous abstinence rates in one study
(Walker 2012).
Considering the other factors that contribute to tobacco depen-
dence, there is interest in developing smoking cessation products
that would not only help relieve the unpleasant effects of nico-
tine withdrawal but would also act as an effective substitute for
smoking behaviour and the rituals and sensations that accompany
smoking, without the health risks associated with the inhalation of
tobacco smoke. The only pharmaceutical treatment available that
has some of these characteristics is the nicotine inhalator. How-
ever, the inhalator does not have greater cessation efficacy than the
other nicotine replacement therapy (NRT) products (Hajek 1999;
Stead 2012). This may in part be due to the considerable effort
(e.g. 20 minutes of continuous puffing) needed to provide nico-
tine blood concentrations consistent with other NRTs (Schneider
2001). Adherence to correct use of the inhalator is low compared
to other NRTs (Hajek 1999). It is therefore possible that any ad-
vantage of sensorimotor replacement is diminished by low nico-
tine delivery and limited similarities between inhalator use and
sensations of smoking (Bullen 2010).
Description of the intervention
ECs are electronic vaporizing devices that have in common the
ability to heat a liquid, usually comprising propylene glycol and
glycerol, with or without nicotine and flavours, and stored in dis-
posable or refillable cartridges or a reservoir, into an aerosol for
inhalation. The commonly-used term for this aerosol is vapour,
which we use throughout the review. ECs are currently being pro-
moted by retailers to use instead of cigarettes when in smoke-free
environments, and to replace conventional cigarettes with a safer
alternative.
ECs provide sensations similar to smoking a cigarette. They pro-
vide taste and throat sensations that are closer to smoking than
those provided by the nicotine inhalator (Barbeau 2013). The
vapour that looks like tobacco smoke is only visible when the user
exhales after drawing on the mouthpiece, not when the device is
being held.
There are hundreds of different brands and models of EC avail-
able. There is also wide variation in the composition of the fluid
in the cartridge or in the EC reservoir (nicotine content, flavours
and other components) (Goniewicz 2012; Goniewicz 2014). This
makes a blanket assessment of cessation efficacy difficult. Con-
clusions should relate to the particular type of EC tested and the
composition of the liquid being aerosolized.
Initial studies showed that the brands of EC tested delivered very
low amounts of nicotine to naïve users (Bullen 2010; Eissenberg
2010; Vansickel 2010). However, the studies suggested that even
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in the absence of good nicotine delivery, these brands of EC could
alleviate urges to smoke. One study allowed a comparison of EC
and inhalator, although itsmain objectivewas a comparisonof ECs
with andwithout nicotine. Puffing for 20minutes on the inhalator
and puffing for fiveminutes on the EC had similar effects on desire
to smoke after overnight abstinence (Bullen 2010). Later studies
that havemeasurednicotine pharmacokinetics in both experienced
(Vansickel 2013) and naïve (Vansickel 2012) EC users have found
that some EC users can achieve blood nicotine levels similar to
those achieved with smoking, albeit more slowly, and that their
ability to do so often improves over time (Hajek 2015b).
At the time of writing, the most popular types of EC include ’ci-
galike’ products that look like cigarettes and are easier to operate
(they are disposable or use cartridges that are just screwed on) and
’tank’ products that include a larger battery and a transparent con-
tainer that users fill with an e-liquid of their choice. The tank ECs
provide better nicotine delivery, allow a wider choice of flavours
and nicotine concentrations, and are typically used by experienced
vapers who managed to switch to vaping altogether (ASH 2016;
Dawkins 2013b; Farsalinos 2014; McNeill 2015). Observational
evidence suggests smokers are more likely to successfully quit us-
ing tank models than with cigalikes, perhaps because of improved
nicotine delivery in these models (Chen 2016; Hitchman 2015).
EC types are also often grouped by ’generation’: first-generation
devices are typically cigalikes; second-generation devices are usu-
ally tank models; and third-generation devices are tank models
which, unlike second generation devices, allow users to adjust the
voltage level of the product (see NCSCT EC briefing for further
information and images of different product types).
Throughout this review we refer to a nicotine-containing EC as
‘nicotine EC’ and to a nicotine-free EC as ‘placebo EC’. The
’placebo’ comparison is a test just of the nicotine effect and not of
the potential sensorimotor replacement that the EC may provide.
Why it is important to do this review
Since ECs appeared on the market in 2006 there has been a steady
growth in sales, with some commentators reporting that ECs are a
threat to the sales of cigarettes (Herzog 2013). This growth in sales
is reflected in population survey data from high-income countries
that show an increased awareness and use of ECs over time (ASH
2016; Agaku 2014; Ayers 2011; Gallus 2014; West 2016). Data
from lower-income countries also suggest high levels of EC use
and awareness (Jiang 2016; Palipudi 2016). ECs are used almost
exclusively by smokers or ex-smokers (ASH 2016; Douptcheva
2013; West 2016). A small proportion of never-smokers have re-
ported trying or experimenting with ECs but they do not seem
to progress to daily or even regular use (ASH 2016; CDC 2013;
West 2016). Of smokers who try ECs, fewer than 15% become
daily users (Douptcheva 2013; Kralikova 2012), which suggests
that ECs are still not an entirely satisfying replacement for smok-
ing.
Regulatory approaches being used for ECs currently vary widely,
from no regulation to complete bans in countries including Sin-
gapore and Brazil. The US Food and Drug Administration has
classified them as tobacco products and is preparing to implement
a regulation that will restrict their sale and use (FDA 2016). The
European Union has included ECs in their Tobacco Products Di-
rective, except where therapeutic claims are made or in instances
where they contain over 20 mg/nl of nicotine, when they will re-
quire medicines authorization (European Parliament 2014).There
is now general agreement that EC use exposes the user to fewer
toxicants than smoking tobacco cigarettes (McNeill 2015; RCP
2016). However, those calling for ECs to be stringently regu-
lated (e.g. Grana 2014a; McKee 2016; WHO 2014) cite the lack
of quality control measures, possible harms of second-hand EC
vapour inhalation, concerns that the products may be a gateway to
smoking initiation, concerns that ECsmay undermine smoke-free
legislation if used in smoke-free spaces, and concerns regarding
the involvement of the tobacco industry. However, other reviews
of available data do not support these concerns or suggest that po-
tential benefits outweigh potential disadvantages (Farsalinos 2014;
Hajek 2014; McNeill 2015; RCP 2016).
Regarding safety, categorical statements about the toxicity of ECs
are not possible because of the large number of devices and fluids
available and the frequent addition of new products to the market.
However, among those brands of EC that have been tested, levels of
toxins have been found to be substantially lower than in cigarettes,
and are present at levels that are unlikely to represent a significant
risk to health to either the user or to bystanders (Hajek 2014;
McNeill 2015). Short- to medium-term use of ECs is associated
with few adverse events (Bullen 2013; Caponnetto 2013a). Long-
term effects beyond 12 months are unknown, although based on
what is known about liquid and vapour constituents and patterns
of use, a recent report from the UK’s Royal College of Physicians
has concluded that using an EC is likely to be considerably safer
than smoking (RCP 2016).
Smokers, healthcare providers and regulators are interested to
know if these devices can help smokers quit and if it is safe to use
them to do so. In particular, healthcare providers have an urgent
need to know what advice they should give to people who smoke.
The largest health gains are achieved from stopping smoking com-
pletely, as opposed to reducing cigarette consumption, and as such
this review focuses on the effectiveness of ECs in aiding smoking
cessation. There is also an opportunity to investigate if the EC
has potential to aid reduction in cigarette consumption in those
smokers who cannot or do not want to stop smoking altogether;
this was covered in the previous version of this review (McRobbie
2014), but is now covered in a separate review (Stead 2007, update
forthcoming).
O B J E C T I V E S
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To evaluate the safety and effect of using electronic cigarettes (ECs)
to help people who smoke achieve long-term smoking abstinence.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) in which smokers are ran-
domized to ECs or to a control condition, and which measure
abstinence rates at six months or longer, to determine the efficacy
of ECs in aiding smoking cessation and reduction. We anticipated
that the search would return few RCTs and so we also consid-
ered the results from cohort follow-up studies with six months’ or
longer follow-up. In this and the previous version of the review, we
include those observational cohort studies which survey existing
smokers at baseline, some of whom are already dual users of EC
and cigarettes. As discussed in further detail below, these studies
are heavily confounded due to the nature of their design. In antic-
ipation of further high-quality studies becoming available, we will
exclude this study design for efficacy outcomes in the next update
of this review, and will only include those observational studies
where an intervention has been provided.
For adverse events and biomarkers, we included randomized cross-
over trials and cohort follow-up studies with follow-up of greater
than a week.
We included studies regardless of their publication status or lan-
guage of publication.
Types of participants
People defined as current smokers at enrolment into the studies.
Participants can be motivated or unmotivated to quit.
Types of interventions
We compare ECs with placebo ECs, ECs versus alternative smok-
ing cessation aids, including NRT or no intervention, and ECs
added to standard smoking cessation treatment (behavioural or
pharmacological or both) with standard treatment alone. As rel-
atively few controlled trials are currently available (some are un-
derway), we also include uncontrolled studies which evaluate ECs
(see Types of studies).
Types of outcome measures
Cessation at the longest follow-up point, which was at least six
months from the start of the intervention, measured on an in-
tention-to-treat basis using the strictest definition of abstinence,
preferring biochemically-validated results where reported.We col-
lected any data on adverse events at one week or longer, serious
and non-serious, from the included studies, including changes in
relevant biomarkers.
Search methods for identification of studies
Electronic searches
We searched the following databases in January 2016:
• Cochrane Tobacco Addiction Group Specialized Register
• Cochrane Central Register of Controlled Trials
(CENTRAL) (the Cochrane Library, 2016, Issue 1)
• MEDLINE (OVID SP) (2004 to 2016 January week 2, &
MEDLINE in process/In data review Feb 1 2016)
• Embase (OVID SP) (2004 to 2016 week 5)
• PsycINFO (OVID SP) (2004 to 2016 January week 4)
For the first version of the review we also searched CINAHL (EB-
SCO Host) (2004 to July 2014). We did not search this database
for this review update as it did not contribute additional search
results to the first version of the review.
The search terms were broad and included e-cig$OR elect$ cigar$
OR electronic nicotine. The search for the 2016 update added the
terms vape or vaper or vapers or vaping. The search strategy for
MEDLINE (Ovid SP) is shown in Appendix 1.
The search date parameters are limited to 2004 to the present, due
to the fact that ECs were not available before 2004.
Searching other resources
We searched the reference lists of studies found in the litera-
ture search and the metaRegister of controlled trials database (
www.isrctn.com/page/mrct). We also contacted authors of known
trials and other published EC studies.
Data collection and analysis
Selection of studies
Two review authors (from JHB, HM, LS or RB) independently
prescreened all titles and abstracts obtained from the search, using
a screening checklist. Where there was disagreement, we obtained
the full-text version and resolved the disagreement by discussion
or by referral to a third review author (PH).
Two review authors (from JHB, HM and RB) obtained and in-
dependently screened full-text versions of the potentially relevant
papers for inclusion. We resolved any disagreements by discussion
or with a third review author (PH).
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Data extraction and management
Two review authors (from JHB, HM or LS) extracted data from
the included studies, and checked them against each other. A third
review author (PH) was available to review and resolve any dis-
crepancies. We extracted data on:
• Author
• Date and place of publication
• Study design
• Inclusion and exclusion criteria
• Setting
• Summary of study participant characteristics
• Summary of intervention and control conditions
• Number of participants in each arm
• Smoking cessation outcomes
• Type of biochemical validation (if any)
• Adverse events (AEs), serious adverse events (SAEs), and
relevant biomarkers
• Assessment time points
• Risk of bias in the domains specified below
• Additional comments
We adopted a broad focus to detect a variety of adverse events.
One review author then entered the data into Review Manager 5
software for analyses, and another checked them.
Assessment of risk of bias in included studies
Two review authors (JHB and HM or LS) independently assessed
the risk of bias for each included study, following the approach
recommended in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). This approach uses a domain-based
evaluation that addresses seven different areas: random sequence
generation; allocation concealment; blinding of participants and
providers; blinding of outcome assessment; incomplete outcome
data; selective outcome reporting; and other potential sources of
bias. We assigned a grade (low, high, or unclear) for risk of bias
for each domain. We resolved disagreements by discussion or by
consulting a third author (PH).
Measures of treatment effect
We analyzed dichotomous data by calculating the risk ratio (RR),
using the longest follow-up data reported. For cessation, we cal-
culated the RR as ((number of events in intervention condition/
intervention denominator) / (number of events in control condi-
tion/control denominator)) with a 95% confidence interval (CI).
We analyzed continuous data (other measures of tobacco expo-
sure) by comparing the difference between the mean change from
baseline to the longest follow-up point in the intervention and
control groups.
Unit of analysis issues
We extracted data on smoking outcomes only fromRCTs in which
individuals were the unit of randomization. In the case of trials
with multiple arms, we combined all relevant experimental inter-
vention groups of the study into a single group, and combined all
relevant control intervention groups into a single control group.
We offer a narrative synthesis of data from cohort studies.
Dealing with missing data
For smoking cessation, we used a conservative approach as is stan-
dard for the Cochrane Tobacco Addiction Group, treating partic-
ipants with missing data as still smoking. We based the propor-
tion of people affected by adverse events on the number of people
available for follow-up, and not the number randomized.
Assessment of heterogeneity
We assessed the clinical and methodological diversity between
studies to guide our decision as to whether data should be pooled.
We were also guided by the degree of statistical heterogeneity, as-
sessed by calculating the I² statistic (Higgins 2003); we considered
a value greater than 50% as evidence of substantial heterogeneity.
Assessment of reporting biases
Reporting bias is best assessed using funnel plots, where 10 or
moreRCTs contribute to anoutcome.However, there are currently
insufficient studies to support this approach.
Data synthesis
We provide a narrative summary of the included studies. Where
appropriate, we have pooled data from these studies inmeta-analy-
ses. For dichotomous data, we used a fixed-effectMantel-Haenszel
model to calculate the risk ratio with a 95% confidence interval,
in accord with the standard methods of the Cochrane Tobacco
Addiction Group for cessation studies.
Wehadplanned to calculate the summary estimates for continuous
outcomes (e.g. biomarkers of tobacco exposure) using the inverse
variance approach (also with a 95% CI). However, there were
insufficient data with which to do so.
For adverse events, we originally planned to enter the most com-
monly-reported adverse events into meta-analyses to determine if
there were any significant differences between the EC and control
groups. We also originally planned to include data from cross-over
trials in a meta-analysis using paired data obtained from reports.
However, there were again insufficient data with which to do so,
and hence we have summarized adverse event data narratively.
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Subgroup analysis and investigation of heterogeneity
We had planned to undertake subgroup analyses to investigate
differences between studies, such as:
• Intensity of behavioural support used;
• Type of control group (e.g. placebo EC, NRT);
• Type of participants (e.g. experience of EC use).
However, there were too few studies to conduct such analyses.
Should further studies become available in future, we will follow
this approach.
Sensitivity analysis
Wehadplanned toundertake sensitivity analyses to assess the effect
of removing studies judged to be at high risk of bias. However,
there were too few studies to conduct such analyses. Should further
studies become available in subsequent updates, we will adopt this
approach.
Summary of findings table
Following standard Cochrane methodology, we created a ’Sum-
mary of findings’ table for both outcomes. For cessation, the ’Sum-
mary of findings’ table only includes data from randomized con-
trolled trials. Also following standard Cochrane methodology, we
used the five GRADE considerations (study limitations, consis-
tency of effect, imprecision, indirectness and publication bias) to
assess the quality of the body of evidence for each outcome, and
to draw conclusions about the quality of evidence within the text
of the review.
R E S U L T S
Description of studies
Results of the search
Our bibliographic database searches identified 1704 non-dupli-
cate records. We found a further six records through screening ref-
erences in the papers identified through electronic searches, and
one further record through author contact. We screened all records
and retrieved the full-text papers of 117 potentially relevant stud-
ies. After screening and checking the full text of 117 papers, we
identified 24 eligible completed studies (11 of which were new for
this update) and eight ongoing studies. Searches of trials registers
for this update identified a further 19 potentially relevant ongo-
ing studies, making a total of 27 ongoing studies (Characteristics
of ongoing studies). We excluded 46 studies after checking full-
text papers (Excluded studies). Secondary study reports, commen-
taries, and correspondence relating to included studies are linked
to studies in the reference section. Figure 1 and Figure 2 present
PRISMA flow charts for the update and the original review, re-
spectively.
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Figure 1. Study flow diagram for review update 2016
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Figure 2. Study flow diagram for original review, 2014
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The completed studies include three RCTs and 21 prospective co-
hort studies that describe abstinence at six months or longer or
adverse events (AEs), or both. In one of the included studies (Choi
2014), the data come from the authors’ response to a criticism of
their paper; the data had not been included in the original study
report. One retrospective cohort study (Polosa 2014a) provided
data on changes in respiratory parameters and symptoms in people
with asthma that were using ECs. Although this used a retrospec-
tive design it used data from different time points and used rou-
tine clinical records that we deemed adequate for capturing data
concerning adverse events.
In this update, we also collected information on systematic reviews
(defined as having run a systematic search of at least one database)
published within the update search period. Appendix 2 lists key
features of the 14 reviews whichmet these criteria; we discuss these
further in Agreements and disagreements with other studies or
reviews.
Included studies
The key features of the included studies are summarized by study
type below. Further details on each included study can be found
in the Characteristics of included studies tables.
Randomized controlled trials
We identified only two completed randomized controlled trials
(Bullen 2013; Caponnetto 2013a) which contribute data on ces-
sation at six months or longer.
The ASCENDtrial (Bullen 2013) randomized 657 smokers (mid-
dle-aged, highly dependent, with one-third being of New Zealand
Maori origin) who wanted to quit to use either an Elusion brand
EC (first-generation technology) with cartridges containing 16mg
nicotine, or 21 mg/24-hour nicotine patches, or an EC with car-
tridges without nicotine (placebo EC), for 12 weeks following a
target quit date (TQD). The ECs were couriered to participants,
and those allocated to the patch arm were mailed a voucher to
exchange for NRT at a pharmacy, which is standard practice in
New Zealand, but also received a voucher to cover the dispensing
costs. All participants received an invitation to access phone- or
text-based support, although this was accessed by fewer than 10%.
The EC used in this study delivered only low levels of nicotine.
This was determined in a subsample of four participants, who had
used the EC for at least one week, volunteered to give a baseline
blood sample, and then use their EC, taking one puff everyminute
over 10 minutes. They then provided five further blood samples at
approximately 10, 20, 30, and 60minutes after the start of EC use.
Pharmacokinetic analyses showed that plasma nicotine concentra-
tions peaked (a median increase of 2.1 ng/ml from baseline) at 10
minutes after the start of EC use. Participants were followed up at
six months post-TQD and self-reported abstinence was validated
by carbon monoxide (CO) in expired breath, in line with the Rus-
sell Standard (West 2005). Participants who were still smoking at
follow-up were asked to report their daily cigarette consumption,
and a change from baseline consumption was measured.
In the three-arm ECLAT trial (Caponnetto 2013a), 300 smok-
ers (again middle-aged and highly dependent), who were not in-
tending to quit smoking in the next 30 days, were randomized to
use a ’Categoria’ brand EC (model 401, which is no longer pro-
duced) with disposable cartridges containing 7.2 mg nicotine or 0
mg nicotine (placebo EC) for 12 weeks. The third arm used car-
tridges containing 7.2 mg nicotine for six weeks followed by 5.2
mgnicotine for another six weeks. The ECwas presented simply as
a healthier alternative to tobacco smoke, and could be freely used
ad libitum (up to four cartridges per day) as a tobacco substitute.
Participants were seen on eight occasions over 12 months, once
at baseline and at seven follow-up visits where they received more
cartridges, handed in smoking diaries, and had CO and vital signs
measured. Abstinence at 12 months was defined as complete self-
reported abstinence from tobacco smoking since the previous visit
at six months, confirmed with CO less than 7 parts per million
(ppm) at six and 12months. Participants whowere still smoking at
follow-up were asked to report their daily cigarette consumption,
and a change from baseline consumption was measured.
New for this update is a further randomized controlled trial,
Adriaens 2014. This three-armed trial randomized 51 smokers not
intending to quit in the near future to either the Joyetech e-GO-C
second-generation EC, theKanger T2-CC second-generation EC,
or to no treatment at baseline. EC groups were provided guidance
on EC use and instructed to use the assigned EC ad libitum. Both
groups were also provided with bottles of tobacco-flavoured e-
liquid containing 18 mg/mL nicotine. At eight weeks, the control
group was given the same ECprovisions, but without instructions.
Participants were followed up at three lab sessions over twomonths
in which biomarkers, mood, adverse events and cessation were
measured, as well as craving, withdrawal, and EC usage. Further
data collection occurred at five and eight months from baseline.
As all groups were provided with nicotine-containing EC by six
months, this study is not included in our meta-analysis of smoking
cessation outcomes and we report results narratively only.
Cohort studies
Six prospective intervention studies (three new for this update)
described abstinence at six months or longer in smokers provided
with ECs and/or instructions on EC use to reduce or stop smok-
ing. Eight further studies (five new for this update) described ab-
stinence in smokers who had tried or used ECs in the past at six
months or longer from baseline (note, we will exclude this group
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of studies from the next version of this review, as higher-quality
data become available). Finally, seven studies (two new for this
update) provide information on adverse events only.
Intervention studies
The first of the intervention studies recruited 14 smokers with
schizophrenia from among inpatients at a psychiatric institution
in Italy (Caponnetto 2013b). All had been smoking at least 20
cigarettes a day for at least the past 10 years and were not in-
tending to quit. Participants were seen at baseline and provided
with an EC (’Categoria’ brand) with an initial four-week supply
of 7.4 mg nicotine cartridges. They were instructed to use their
EC ad libitum (up to four cartridges a day), but no instruction
on cessation or reduction was provided. Follow-up was completed
at 1, 2, 3, 6 and 12 months when cigarette consumption, CO,
AEs and positive and negative symptoms of schizophrenia were
measured. Further EC cartridges were supplied at one, two, and
three months.
Another similarly designed study examined the effects of EC use
over an extended period of time in 40 highly dependent middle-
aged smokers not wanting to quit smoking at any time in the next
30 days, recruited from among staff working in an Italian hospi-
tal (Polosa 2011). At baseline they were given an EC (’Catego-
ria’ brand) with a four-week supply of 7.4 mg nicotine cartridges
and instructed to use ad libitum (up to four cartridges a day). No
instruction on cessation or reduction was provided. Participants
were followed up at 1, 2, 3, 6, 18 and 24 months, when cigarette
consumption, CO, and AEs were recorded. Additional EC car-
tridges could be requested at months one, two, and three.
The third study (Ely 2013) recruited 48 smokers, who wanted to
quit or switch from cigarettes to ECs, from among 640 patients
of a single family medical practice in Colorado (USA) who were
recorded as current smokers. The intervention was based on the ’5
As’ and the transtheoretical model, and participants were informed
of the range of treatment options at the start of the programme.
They were provided with written information on ’blu cig’ and
’smoke tip’ ECs, regarding cost, availability, and nicotine dosage
options. All participants used an EC, with 16 using bupropion
and two using varenicline as well. Follow-up was undertaken by
telephone at two weeks, one, three and six months after the start
of the intervention. No definition of abstinence was provided, nor
were self-reports biochemically verified.
The fourth study (Pacifici 2015), new for this update, recruited
34 adult smokers who had never received stop-smoking support
and were unmotivated to quit from a hospital-based smoking ces-
sation clinic in Italy. Participants were naïve to EC use at base-
line and were provided with a commercially available EC over a
period of four weeks, starting with a nicotine-free e-liquid before
moving to a personally-tailored nicotine dosage. Participants were
offered a multicomponent medically-assisted training programme
for EC use, and were followed up at one, four and eight months
where cessation, cigarettes per day, adverse events, exhaled CO,
and nicotine concentration were measured.
The fifth study (Polosa 2014b), also new for this update and also
based in a smoking cessation clinic in Italy, recruited 50 smokers
unwilling to quit who had been smoking at least 15 cigarettes a
day at baseline for at least 10 years. Participants were provided
with second-generation ECs with 9 mg/ml nicotine e-liquid, and
instructed to use the products ad libitum. No encouragement to
quit smoking was provided, but participants were supported in
charging, filling, activating and using the EC, with phone numbers
provided for assistance. Thirty-day, biochemically-verified point
prevalence abstinence, adverse events, cigarettes per day, exhaled
CO and data on product usage and opinions of the product were
collected at 4, 8, 12 and 24 weeks.
The final study (Polosa 2015), also new for this update, recruited
71 adult smokers making their first EC purchase from vape shops
across Catania province in Italy. Participants were not provided
with ECs but, upon purchasing an EC product of their choice,
were instructed on how to set up and use the device and were
given troubleshooting advice and a phone number for technical
support. Participants were encouraged to use the EC in antici-
pation of reducing their daily cigarette consumption. Thirty-day
self-reported point prevalence abstinence, details of product pur-
chase, and cigarettes smoked per day were collected at six and 12
months.
Non-intervention studies
We include three longitudinal web-based surveys in this review.
The first (Etter 2014) followed up smokers and EC users access-
ing websites selling or informing users about ECs and online EC
forums. The survey was open to all nationalities, with 34% of re-
spondents from theUSA, 24% fromFrance, 8% from theUK, 6%
from Switzerland, and 28% from other countries. Three hundred
and sixty-seven participants who had completed a baseline ques-
tionnaire also completed a follow-up survey one year later when
they were asked to provide follow-up data on EC use and smok-
ing behaviour. Of these participants, 35 (10%) were occasional or
daily smokers and daily EC users at baseline.
In the second web-based survey, Grana 2014b recruited 949 cur-
rent cigarette smokers (59% smoked within 30 minutes of waking
and 69% never expected to quit or did not intend to quit in the
next sixmonths), who completed surveys at both baseline and one-
year follow-up. At baseline 9% (n = 88) were using ECs (defined
as use in the past 30 days). Self-reported abstinence (not defined)
was measured at one-year follow-up.
In the final web-based survey, Brose 2015 recruited 4064 UK res-
idents who had smoked in the past year, with 1769 followed up at
12 months. Twenty-three per cent of participants were EC users at
baseline, themajority of whom indicated theywere using first-gen-
eration ECs. At follow-up, data were collected on quit attempts,
reduction in cigarettes per day, and whether the participant con-
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sidered him- or herself to be an ’ex-smoker.’
Two longitudinal telephone-based surveys are included in this re-
view. In the first (Al-Delaimy 2015), which is new for this update,
California residents (USA) were recruited, who had smoked at
least 100 cigarettes in their lifetime and smoked cigarettes ’at least
some days’ at baseline. At baseline, 83.6% were daily smokers,
236 had used ECs, and 306 indicated they would never use ECs.
Self-reported prolonged abstinence for one month or longer, quit
attempts, and reduction were assessed at 12 months.
In the second study (Choi 2014), authors presented new data from
a prospective cohort study of young adults recruited from Mid-
western states of the USA in a response to a letter criticizing their
main paper, which did not provide data on EC users and smok-
ing outcomes. The letter reports on smoking cessation outcomes
(not defined) in a sample of smokers who used ECs for one or
more days in the last 30 days at baseline (no N given), comparing
these to a sample of baseline smokers who had never used ECs at
baseline. The main paper included 1379 participants (mean age
24) who had never used ECs, 17.8% of whom were reported to
be current smokers.
A final three prospective studies used a range of follow-upmethods;
all are new for this update. Borderud 2014 recruited 1074 patients
presenting with cancer at a large US cancer centre who were re-
ferred to and completed intake assessment for the centre’s tobacco
cessation programme. All participants were offered multicompo-
nent, evidence-based behavioural and pharmacological treatment
for tobacco dependence. At baseline, 26.5% of participants had
used an EC within the last 30 days. Seven hundred and eighty-
one participants were followed up at six to 12 months from base-
line, where self-reported seven-day point prevalence abstinence,
cigarettes per day, and information on whether a participant had
gone a day without smoking since baseline were collected.
In Manzoli 2015, which took place in community settings in
Abruzzo, Italy, 491 tobacco smokers and 232 dual EC and to-
bacco smokers were followed up at 12 months, with further fol-
low-ups planned at 24, 36 and 60 months. At baseline, the mean
EC nicotine dosage was 9.8 mg/ml, and the mean months of EC
use amongst dual users was 8.6. Follow-up measures included 30-
day sustained abstinence with CO verified in a subsample, and
30-day abstinence from tobacco and EC.
Finally, Prochaska 2014 reports a secondary analysis of data from
a randomized controlled trial in an inpatient psychiatric hospital
in California, USA. Nine hundred and fifty-six smokers of at least
five cigarettes a day were recruited and randomized to different
levels of behavioural support. At baseline, 11% of participants
used an EC. This paper reports cessation measures (not defined)
in EC and non-EC users at the longest available follow-up (not
defined, but study length was 18 months).
Adverse event data only
We include seven short-term cohort studies that report on adverse
events. These studies are not included in smoking analyses due
to short follow-up. Again, further details can be found in the
Characteristics of included studies tables.
Hajek 2015a offered an EC to 100 smokers joining a stop-smok-
ing service in London, UK. Participants were offered a choice of a
‘cigalike’ product (Gamucci, 1.6% or 2.2% nicotine per ml) or a
tank model (EVOD, 1.8%; later replaced with Aspire product due
to leakage issues), and 69% took up the offer. The ECs were pro-
vided alongside standard stop-smoking service provisions, includ-
ing an offer of stop-smoking medications and weekly behavioural
support. Adverse events were collected throughout. The study also
measured abstinence at four weeks, cost, and client feedback.
Humair 2014 describes a prospective cohort study involving 17
participants (all highly dependent smokers, 82% with a mental
illness), recruited from a university hospital outpatient clinic in
Switzerland, who chose to use an EC to help them stop or reduce
smoking. NRT or varenicline were used at some stage by 59%
of participants in addition to EC. This study was available as an
abstract only and thus we have limited detail on the methods and
measures used to record adverse events.
McRobbie 2015 recruited 40 daily smokers who wanted to quit,
from advertisements placed in free London newspapers. Partici-
pants attended a baseline session one week prior to their target quit
date (TQD). On the TQD, participants were provided with ECs
(’Green Smoke’, first-generation device, 2.4%nicotine cartridges).
Two cartridges a day were supplied initially, with the supply later
adjusted to actual usage. Participants attended weekly follow-up
sessions for four weeks, and received standard behavioural sup-
port. Cigarette consumption and CO readings collected at each
session and urine samples for cotinine and 3-hydroxypropylmer-
capturic acid (3-HPMA) analysis were collected at baseline and at
four weeks post-TQD.
Nides 2014 recruited 29 smokers in good health and not intend-
ing to reduce or quit smoking in the next 30 days. The aim of
this study was to investigate nicotine delivery and potential for
smoking reduction or cessation. Participants were provided with a
10-day supply of disposable ECs (’NJOY King Bold’ brand con-
taining 26 mg of nicotine) and instructed to use them ad libitum
for a week. At the end of the week, 25 participants returned to the
clinic, after abstaining from smoking and EC use for 12 hours.
They undertook two series, an hour apart, of 10 puffs on their
EC, and changes in plasma nicotine, heart rate and CO, and with-
drawal symptoms were measured. Adverse events that occurred
during the period of ad libitum use were also collected.
Oncken 2015 describes a randomized cross-over study involving
27 non-treatment-seeking smokers of at least 10 cigarettes a day
who were willing to try ECs for two weeks. Participants were pre-
scribed Joye e-GO C with 18 mg/ml nicotine, and crossed over
at one week between menthol flavour and non-menthol tobacco-
flavoured ECs. Participants were requested not to smoke during
the study, but 60% reported intermittently using their normal
cigarettes. At one and two weeks, blood pressure, heart rate, body
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plethysmography, static lung volumes, airways resistance (Raw)
and specific conductance (sGaw) were measured after abstaining
fromEC for two hours and, subsequently, five minutes after inhal-
ing an EC. Data on adverse events, nicotine concentrations and
rates of cigarette and EC use were also collected.
Although not a prospective cohort study, Polosa 2014a allowed for
extraction of data regarding adverse events. This study identified
18 participants withmild-to-moderate asthmawhohad previously
smoked an average of 22 cigarettes a day, who reported regular EC
use on at least two consecutive follow-up visits, approximately six
months apart, using a retrospective audit of clinical records from a
respiratory outpatient clinic in Italy. Ten were using ECs only, and
eight used ECs and smoked up to five cigarettes a day. The dura-
tion of EC use ranged from 10 to 14 months, and all started on
first-generation ECs, though the ’majority’ switched to a “personal
vaporiser” (second- or third-generation). The authors collected
data from four clinic visits: pre-baseline (6 to 12 months prior
to baseline); baseline visit (pre-EC use), which occurred approxi-
mately six months prior to the first follow-up visit; six-month fol-
low-up; and 12-month follow-up. At each visit, participants were
assessed by clinical history and examination, and by re-evaluation
of treatment adherence and efficacy. Information was gathered on
asthma control, the number of exacerbations from the previous
follow-up visit, spirometry measurements, forced expiratory flow,
and bronchial provocation tests assessing Airway Hyper Respon-
siveness (AHR) with methacholine (some participants only).
Van Staden 2013 recruited 15 healthy smokers of at least 10
cigarettes a day from a military hospital in South Africa. They
were each provided with an EC (’Twisp eGo’ 18 mg/ml nicotine)
and asked to use this and to stop smoking for two weeks. Blood
pressure, pulse, arterial and venous carboxyhaemoglobin satura-
tion (COHb) and blood oxygen saturation weremeasured at base-
line and two-week follow-up in 13 participants that attended both
sessions.
Excluded studies
The reasons for exclusion of the 46 studies that we reviewed are
briefly summarized below, but further detail can be found in the
Characteristics of excluded studies table.
We ruled out the majority of excluded studies because the partici-
pants used ECs for less than a week, or the study report contained
no information on cessation or adverse events. In these cases we
were unable to determine if the excluded studies intended to mea-
sure these outcomes. In line with our protocol, we excluded cross-
sectional studies with data collected at one time point only, for rea-
sons including inability to control for confounding variables and
recall bias (see Agreements and disagreements with other studies
or reviews for further discussion of potential biases).
Risk of bias in included studies
The risk of bias in the two RCTs which contribute to the ces-
sation meta-analysis (Bullen 2013; Caponnetto 2013a) was low
across all domains. The only exception was in the reporting bias
in Caponnetto 2013a, as it was unclear if the original intention
was to combine the two nicotine-containing EC groups or not.
In the sample size calculation the authors compared the nicotine
EC group with the placebo EC, but results are not reported in
this way. In both studies the randomization procedures were ade-
quate, biochemical validation of abstinence was used, and an in-
tention-to-treat analysis was undertaken where all participants lost
to follow-up (LTFU) were considered to be smoking. The lost-
to-follow-up rate in Bullen 2013 was 22%. Although the patch
grouphadhigher LTFUandwithdrawal than theECgroup (patch:
27%; nicotine-EC: 16%; placebo EC: 22%), there was minimal
difference between the per-protocol and ITT analyses and so we
deemed attrition bias to be at low risk. LTFU rates were similar
among the three arms at 12 months in Caponnetto 2013a (35%
in 7.2 mg nicotine group; 37% in 5.4 mg nicotine group; 45% in
no-nicotine group). In the randomized cross-over trial (Oncken
2015), we judged the risk of selection, performance and detection
bias to be unclear, due to the limited amount of detail provided.
We rated attrition and selection bias as low, with 20 out of 27
participants followed up and all expected outcomes reported. In
Adriaens 2014, a further RCT not included in the cessation meta-
analysis, we judged allocation concealment and attrition bias to be
unclear, due to limited detail available; we rated all other domains
as low risk of bias.
We categorized all other included studies, by nature of their design,
as being at high risk of selection bias. Ten of these did not blind
participants or personnel and, given the nature of the study, follow-
upmeasures and contact with researchers, we judged them to be at
risk of selection or performance bias or both. In the other studies,
the lack of intervention or contact with researchers means that
there is unlikely to be significant performance or detection bias.
Rates of follow-up were mixed in the non-randomized studies,
with four judged to be at risk of attrition bias because of high or
differential levels of follow-up. For many of the cohort studies we
were unable to determine prespecified outcomes and hence rated
these as being at unclear risk of reporting bias. One cohort study
stated they collected data on adverse events, but did not provide
any results for this outcome measure, and we judged it to be at
high risk of reporting bias (Pacifici 2015). Finally, Ely 2013 did
not provide a definition of abstinence and it was unclear if the
completion of the programme was at six months after enrolment,
or at an earlier time point. We therefore judged this study to be at
high risk of other bias.
Details of ’Risk of bias’ judgements for each domain of each
included study can be found in the Characteristics of included
studies table. Figure 3 illustrates judgements for each included
study.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison Electronic
cigarettes for smoking cessation
In this section we have summarized the effects of ECs on smoking
cessation and adverse events.
Cessation
Randomized controlled trials
In the trial comparing EC to patch (Bullen 2013) there was no
significant difference in six-month CO-validated continuous ab-
stinence between the treatment arms (7.3%, 5.8% and 4.1%, in
the nicotine EC, patch and placebo EC arms respectively). We
made two comparisons. The first compares abstinence rates be-
tween nicotine and placebo EC (7.3% versus 4.1%, risk ratio (RR)
1.77, 95% confidence interval (CI) 0.54 to 5.77; 362 participants;
Analysis 1.1). The second compares abstinence rates between the
nicotine EC and patch arms (7.3% versus 5.8%, RR 1.26, 95%CI
0.68 to 2.34; 584 participants; Analysis 1.2). Fewer than half of
all participants across all groups accessed support (39.8%, 35.9%,
and 35.6% in the nicotine EC, patch and placebo EC arms re-
spectively).
In the other RCT (Caponnetto 2013a) one-year abstinence rates
(at least six months of not smoking andCO-validated) were higher
in the two nicotine EC arms (13% and 9%) compared with the
placebo EC group (4%). In our analysis we combined the two
nicotine EC arms and compared these with the placebo group.
The difference was not statistically significant (11% versus 4%,
RR 2.75, 95% CI 0.97 to 7.76; 300 participants; Analysis 1.1).
We combined data from the two studies comparing abstinence
rates in nicotine versus placebo EC groups. There was no signif-
icant statistical heterogeneity between the studies (Chi² = 0.30,
P = 0.58; I² = 0%) and pooled results showed use of a nicotine-
containing EC was associated with higher abstinence rates than
placebo EC use (RR 2.29, 95% CI 1.05 to 4.96, 662 participants;
Analysis 1.1).
Cohort studies
The abstinence rates from each cohort study are summarized in
Table 1.
Intervention studies
Among the intervention cohort studies that enrolled smokers un-
motivated to quit, Polosa 2011 reported abstinence rates (30-
day point prevalence, CO-validated abstinence) of 22.5% at six
months and 12.5% at two years. Pacifici 2015 reported cessation
rates of 52.9% at 12 months, but did not define how cessation was
measured. Polosa 2014b reported 36% (18/50) seven-day point
prevalence abstinence rates at 6 months, which were CO-vali-
dated. In the study of highly-dependent smokers with schizophre-
nia, 14% (2/14) achieved abstinence (CO-validated) at one year
(Caponnetto 2013b). In Ely 2013, 43.8% (21/48) of participants
were abstinent from smoking at the completion of the six-month
programme.Of those that exclusively used ECs (n = 26), 50% (13)
were abstinent, compared with 37.5% (6/16) of those who used
both ECs and bupropion, and 100% (2/2) who used ECs with
varenicline. In the one intervention cohort study in which moti-
vation to quit was not defined (Polosa 2015), 42.2% of partici-
pants (30/71) were abstinent at six months, with similar numbers
at 12 months (40.8%, 29/71; 30-day, self-reported point preva-
lence abstinence). In Adriaens 2014, a randomized controlled trial
in which all participants were provided with nicotine-containing
ECs at eight weeks, and which we hence treat as a cohort study for
cessation purposes, 19.6% of participants were abstinent at eight
months (10/51) using CO validation.
Longitudinal surveys
The longitudinal surveys from the first version of this review con-
tained relatively few smokers whowere using ECs at baseline. Etter
2014 showedone-year self-reported abstinence rates of 45.7%(16/
35) among the responders who used ECs at baseline. In Grana
2014b the one-year abstinence rate was 10% (9/88) in smokers
who had used ECs (at least once in the last 30 days) at baseline,
compared with 13.8% (119/861) in non-EC users. The difference
between EC and non-EC users was not statistically significant. No
information was provided on whether people were using ECs for
the purpose of cessation or reduction prior to baseline, or whether
they used any EC at all during the follow-up period. Choi 2014
only reported that 11% of smokers who had used ECs for one day
or more in the last 30 days at baseline had quit smoking at one-
year follow-up, compared with 17% of smokers who had never
used ECs. After adjusting for demographics and baseline cigarette
consumption, the odds of quitting were not significantly different
between EC users and people who had never used ECs (odds ratio
(OR) 0.93, 95% CI 0.19 to 4.63). Again, no information was
provided on whether the participants used ECs during the follow-
up period.
Reflecting the increase in EC usage, some of the longitudinal sur-
veys added during this review update had a higher baseline preva-
lence of EC use than those included previously. Al-Delaimy 2015
found one-year self-reported prolonged abstinence (one month or
longer) rates of 5% (12/236) in people who reported ever using
EC at baseline, compared to 10.5% (32/306) in participants who
indicated theywould never use EC at both baseline and follow-up;
the authors report that ever use of EC predicted a lower likelihood
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of cessation in a multivariable analysis (OR 0.41, 95% CI 0.18
to 0.93). In Borderud 2014, 14.5% (denominator unknown) of
participants who reported EC use in the past 30 days at baseline
were abstinent at 12 months (self-reported seven-day point preva-
lence abstinence), compared with 30% of non-EC users. In an
ITT analysis correcting for a range of predictors, non-EC users
were found to bemore likely to quit than EC users (OR 2.00, 95%
CI 1.23 to 3.26), although there was no significant difference in
a complete-case analysis. It was not possible to calculate ITT data
for Brose 2015; at one year, 8.1% of people who reported daily
EC use at baseline (7/86) reported being ex-smokers, compared
to 9.5% (25/263) of people who reported non-daily EC use at
baseline and 12.9% (168/1307) of non-EC users. Compared with
non-use, daily EC use at baseline was not significantly associated
with cessation at follow-up (OR 0.62, 95% CI 0.28 to 1.37), nor
was non-daily EC use. InManzoli 2015, sustained (30-day) smok-
ing abstinence was reported at 12 months, with CO validation in
a subsample of participants. The authors report there was no sig-
nificant difference in abstinence between EC users and non-users
(summary statistic not provided), with 16% (51/319) of those
who reported baseline EC use abstinent at 12 months compared
with 15% (101/693) of people who did not use EC at baseline.
Finally, Prochaska 2014 also did not find a significant difference
in cessation (definition not provided) between those using EC and
non-users; at the longest available follow-up point, 21% of people
reporting EC use at baseline were abstinent, compared to 19% of
those not reporting EC use at baseline (P = 0.726).
Crucially, this group of studies (the longitudinal surveys) share a
serious limitation. As these studies only recruited current smokers,
they excluded those people from the same population who tried
ECs and stopped smoking (e.g. if 100 smokers tried ECs and 50
stopped smoking, these studies would only recruit the 50 who
continued to smoke). Following up ‘treatment failures’ is likely to
show a low treatment effect, even for treatments that are highly
effective. To asses the effects of ECs on smoking, participants need
to be recruited prior to initiating EC use. In future versions of this
review, as higher-quality data become available, we will no longer
include this group of studies.
Adverse events
None of the RCTs or cohort studies reported any serious adverse
events (SAEs) that were considered to be plausibly related to EC
use.
Of the people available for six-month follow-up in the ASCEND
trial (Bullen 2013), 44.4% of participants in the nicotine EC arm
reported any AEs, compared with 44.7% and 45.6% in the patch
and placeboEC arms respectively.Differences were not statistically
significant (nicotine versus placebo EC: RR 0.97, 95% CI 0.71
to 1.34; 298 participants; Analysis 2.1; nicotine EC versus patch;
RR 0.99, 95% CI 0.81 to 1.122; 456 participants; Analysis 2.2).
The ECLAT trial (Caponnetto 2013a) found no difference in
frequency of AEs at three- or 12-month follow-up between the
three groups. AEs were also measured at baseline, with the five
most frequently reported being cough (26%), dry mouth (22%),
shortness of breath (20%), throat irritation (17%), and headache
(17%). In all groups the frequency of AEs decreased significantly
over time, with the exception of throat irritation.
The cohort studies show a similar picture, with mouth and throat
irritation being the most frequently reported AEs in EC users,
most commonly dissipating over time. In Nides 2014, where par-
ticipants used ECs for one week, 12 participants experienced 15
AEs and all but one (throat irritation) were classified as mild. Af-
ter two weeks of use, Van Staden 2013 documented that 54%
of participants (7/13) reported reduction in phlegm compared
with baseline, whilst 31% (4/13) reported an increase. Changes
in phlegm production could also be secondary to stopping smok-
ing (the majority also reported an improved sense of taste, smell
and an increase in appetite). There was one dropout due to illness
(headache and fever), but it is unclear if this was deemed to be
related to EC use or not. InOncken 2015, where participants used
ECs for two weeks with cross-over at one week between menthol
and non-menthol tobacco-flavoured e-liquid, AEs included cough
in 19% of participants (5/27) , mouth/throat irritation in 15%
(4/27), nausea in 4% (1/27), headache in 4% (1/27), and “other”
in 4% (1/27) (irritability, stomach cramps). This study reported
one severe adverse event (itchy throat and cough) in a partici-
pant with a history of childhood asthma; the participant was dis-
continued from EC use and symptoms resolved. In Polosa 2011,
which reported longer-term follow-up, the most commonly re-
portedAEswere throat irritation (8.7%),mouth irritation (8.7%),
dry cough (13.1%), dry mouth (4.3%), and headache (4.3%),
which were stable throughout the study (percentages represent 24-
month data). Dizziness and nausea had been reported at the start of
the study but disappeared by 24 months. In Polosa 2014b, where
AEs were measured over six months of EC use, throat/mouth ir-
ritation (35.6%), dry throat/mouth (28.9%), headache (26.7%)
and dry cough (22.2%) were frequently reported at study start
but all decreased in frequency over time. In Hajek 2015a, where
AEs were collected over four weeks, throat irritation and minor
coughing were reported (incidence not quantified). The authors
report one incident of a leak from the EVOD system which re-
sulted in mouth irritation; medical treatment was not sought and
the incident was resolved by washing the lip with water. Adriaens
2014 did not systematically collect data on AEs but did collect
’complaints’ through online diaries; across all groups; these in-
cluded bad taste, dry mouth/throat, irritated mouth/throat, dizzi-
ness, headache, nausea, and increased heart rate/palpitations, al-
though rates were not provided. The authors note no significant
change in Beck Depression Inventory scores (from 5.79 (stan-
dard deviation (SD) 8.35) at baseline to 4.94 (SD 8.76) at eight
months). Humair 2014 reports only that participants did not ex-
perience any AEs. Pacifici 2015 reports measuring AEs but does
not report the resulting data.
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Effects on specific parameters
Eight studies report the effects of at least one week of EC use on
more specific parameters.
InAdriaens 2014, which randomized participants to ECor control
at baseline and then provided all participants with EC at eight
weeks, authors report changes over time within groups but do not
report direct between-group comparisons. Expired CO did not
change significantly between baseline and eight weeks in the EC
group (P = 0.10), but increased significantly in the control group
during this period (P < 0.001). At eight months (by which time
all groups had received EC) there was a significant decrease in CO
in all groups compared with baseline (P < 0.01, mean baseline
CO 17.58 ppm (SD 7.17), mean CO at eight months 11.56 ppm
(10.41)).
McRobbie 2015, a prospective cohort study in which all partici-
pants were provided with an EC, assessed the change in 3-HPMA,
the main metabolite of acrolein, excreted in urine after four weeks
of EC use. Acrolein is a carcinogen and is present in cigarette
smoke and some EC vapour (Bein 2011). There is a concern that
people that use EC and smoke may be exposed to higher levels
of acrolein than smoking alone. Of the 33 people that completed
four-week follow-up, 16 were EC users only, and 17 were dual
users. Both groups showed a significant decrease in 3-HMPA in
ng/mg creatinine (EC users: 1623 (SD 850) to 343 (SD 178), P <
0.001; Dual users: 2443 (SD 1105) to 969 (SD 807), P < 0.001).
CO levels (ppm) also showed a significant decrease over time in
both groups (EC users: 15 (SD 8) to 3 (SD 2), P < 0.001; Dual
users: 23 (SD 11) to 11 (SD 8), P = 0.001).
Pacifici 2015 tested exhaled CO at one, four and eight months
in an uncontrolled pre-post pilot study. At one month, EC users
showed a significant decline in exhaled CO; there was no signif-
icant change in non-EC users (people who had opted not to use
the EC provided). At four and eight months, exhaled CO had de-
clined in EC and non-EC users. Polosa 2011, a prospective cohort
study in which all participants were provided with EC, measured
exhaledCO and found a significant reduction in the average across
the whole cohort of 23.5 to 8 ppm at 24 months (P = 0.011).
Polosa 2014b, a further prospective cohort study in which all par-
ticipants were provided with EC, also measured exhaled CO but
report results graphically by group; at 24 weeks, CO appears to
have significantly reduced amongst quitters and people reducing
cigarette consumption by at least 50%, and appears to have re-
mained stable in people who continued smoking at least half as
many cigarettes as they had at baseline.
In the randomized cross-over trial of menthol versus non-menthol
tobacco-flavoured e-liquid (Oncken 2015), the authors found no
significant differences in airway function (Raw or sGaw) over the
course of the two weeks compared to baseline (P > 0.09), or five
minutes after inhalation of either type of EC (P > 0.1). There were
also no significant changes in heart rate or blood pressure in either
group at any time point.
In the retrospective study of smokers with asthma who had be-
come regular EC users (Polosa 2014a), there was no evidence of
harm. On the contrary, there were significant improvements in
asthma control, measures of lung function, and airways hyper-
responsiveness both in EC users only (n = 10) and in dual users
(n = 8) over the 12-month follow-up period. There was a slight
decrease in the number of asthma exacerbations, but this was not
statistically significant (1.17 to 0.78, P = 0.153).
Van Staden 2013, a short-term pre-post study which measured
outcomes after two weeks of EC use, showed that smokers who
switched to ECs had significant improvement in blood oxygen
saturation (96.15% (SD 1.76) to 97.49% (SD 1.34); 1.34% in-
crease, 95% CI 0.60 to 2.08; P = 0.002) and reduction in arterial
(1.95%, 95%CI 0.47 to 3.44; P = 0.01) and venous (1.87%, 95%
CI 0.38 to 3.36; P = 0.02) carboxyhaemoglobin levels.
D I S C U S S I O N
Summary of main results
This update includes a further 11 studies. However, no new ran-
domized controlled trials (RCTs) evaluating smoking cessation at
six months or longer were available, and the conclusions of this
review have not substantively changed. As with the previous ver-
sion of this review, a meta-analysis that pooled the results of two
randomized controlled trials (RCTs), covering 662 participants,
showed that smokers who used nicotine electronic cigarettes (ECs)
were significantly more likely to stop smoking than smokers using
placebo ECs. The effect size (5%) is small, but not unusual given
the low level of behavioural support provided. There was no evi-
dence of statistical heterogeneity, despite the differences in study
designs. In the one trial that evaluated it, a first-generation EC
with low nicotine delivery was as effective as nicotine patches in
helping smokers to quit long-term, but confidence intervals were
wide.
Although the two RCTs were well conducted and judged to be at
low risk of bias, we categorize the quality of the evidence overall
as low, because of the small number of trials on which it is based
(see Summary of findings for the main comparison).We would be
more confident in the findings were there more studies available,
and are encouraged by the increase in ongoing studies collected as
part of this review update.
None of the included studies reported serious adverse events con-
sidered possibly related to EC use. One of the included studies
detected a severe adverse event considered possibly related to EC
use, which was the advent of itchy throat and cough in a par-
ticipant with a history of childhood asthma. This resolved once
EC use was discontinued (Oncken 2015). No studies detected a
significant increase in adverse events in people using ECs. The
most commonly reported AEs were local irritation of the throat
and mouth. One of the RCTs (Caponnetto 2013a) measured AEs
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at baseline and then across the study duration, and showed that
the frequency of respiratory symptoms (e.g. cough and shortness
of breath) decreased over time, which is likely to be secondary to
changes in cigarette smoking. This finding was supported by data
from observational cohort studies.
Overall completeness and applicability of
evidence
This is a new and rapidly evolving field of research. The search for
the first version of this review captured almost 600 publications;
for this update, our searches returned a further 1117 references.
While we are confident that this represents the full range of data
for the time period searched (to January 2016), there may be
unpublished studies thatwe didnot find.Despite the large number
of publications returned, there were relatively few that contain
empirical data and meet our inclusion criteria. The increase in
ongoing studies suggests the evidence base will be strengthened in
coming years.
We relied predominantly on RCTs for smoking cessation. Only
two met our inclusion criteria. This limits the strength of our
conclusions. We were unable to do many of the planned analyses
because of insufficient data.
The designs of the two included RCTs limit the interpretation of
the findings. The ECLAT study (Caponnetto 2013a) used only a
placebo EC control, which does not allow comparison with stan-
dard smoking cessation treatments. The ASCEND trial (Bullen
2013) was more pragmatic, but also has some limitations. For
example, few people accepted the offer of telephone-based be-
havioural support. This is a likely reason for low absolute absti-
nence rates across all arms. The pragmatic nature of the study also
resulted in some differences in the way that participants received
their allocated product (EC was couriered directly to participants,
whereas nicotine patches were supplied via a voucher that partic-
ipants had to take to a community pharmacist). This approach
has been criticized, as this difference may have influenced the out-
comes (Grana 2014a). However, the trial was trying to replicate
standard practice, and sensitivity analyses did not suggest that this
was a mediator.
Both studies used first-generation cartridge ‘cigalike’ ECs that were
widely available at the time but that have now been surpassed by
newer models. The EC used in the ASCEND trial (Bullen 2013)
delivered little nicotine and not particularly quickly (Cmax of 1.3
ng/ml was achieved after 10 minutes of use). The EC used in
the ECLAT trial (Caponnetto 2013a) also performed poorly and
was discontinued before the trial was published. This may have
yielded a more conservative estimate than would be seen with
newer models. If these poorly-performing EC products can assist
smokers, products with better nicotine delivery may have better
effects.
This update includes additional data on cessation from nine fur-
ther studies. The newly-added intervention cohort studies show
a similar response to EC (with quit rates ranging from 14% in
smokers with mental illness to 53% in a population of smokers
unwilling to quit at the outset). This update also includes newly-
added longitudinal surveys. These studies share a serious limita-
tion, as they include only continuing smokers at baseline, mean-
ing people who have successfully used EC to quit prior to baseline
are not included in the study populations; as higher-quality data
become available, we will not include this study type in future
updates of this review. Of the seven longitudinal surveys which
analyzed cessation at follow-up based on EC use at baseline, five
detected no significant difference based on baseline EC use, and
two found that EC use at baseline was significantly associated with
decreased rates of abstinence at follow-up.
The adverse effects described in both the RCT and cohort studies
are similar, regardless of the brand of EC used or nicotine con-
tent, with placebo and nicotine-containing ECs showing similar
numbers and types of adverse events in direct comparisons. They
also reflect what is reported in survey data (Dawkins 2013b; Etter
2011), so we believe that they are broadly applicable to most EC
brands. The common adverse effects, i.e. mouth and throat irrita-
tion, are likely to be caused by the propylene glycol (a humectant)
and nicotine, which has a distinctive hot/peppery taste.
There has been concern raised that dual use may expose people
to greater health risks, including higher nicotine levels. However,
given that people who smoke like to maintain relatively stable
blood nicotine levels (Russell 1990), receiving nicotine from an
alternative source (i.e. EC) is likely to reduce nicotine intake from
cigarettes, which should be accompanied by a reduction in smoke
and toxin intake (Fagerström 2004). In a study assessing biochem-
ical changes exclusively in dual users, there was a significant de-
crease in cotinine, exhaled carbon monoxide levels, and urinary 3-
HMPA (McRobbie 2015). These results are supported by longer-
term studies in smokers provided with ECs, which found decreases
in exhaled carbon monoxide among dual users, and no significant
increases in cotinine levels across the study populations (Adriaens
2014; Pacifici 2015; Polosa 2011; Polosa 2014b).
Quality of the evidence
The RCTs from which we extracted data for this review were con-
ducted to a high standard, with adequate randomization, treat-
ment allocation and blinding, and the abstinence data are reported
in line with accepted standards, including biochemical validation
of self-reported smoking status. We consider these studies to be
at an overall low risk of bias. However, as there were only two of
them, the body of evidence is limited and we consider it to be low
or very low quality by GRADE standards, because of the small
number of trials. These GRADE ratings reflect low levels of con-
fidence in the effect estimates presented in this review. This low
level of certainty in the findings does not reflect issues with the
quality of the individual studies, but rather reflects imprecision
arising from low event rates and wide confidence intervals around
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the estimated effects, and some indirectness due to poor nicotine
delivery in one of the devices tested.
It was unclear if the ECLAT trial (Caponnetto 2013a) intended
to combine the two EC arms in the analysis or not. In sample size
calculation they compared ECs with placebo ECs, but results are
not reported in this way. The rationale for examining two very
similar EC arms is not obvious to the review authors.
Both RCTs were underpowered. The sample for the ASCEND
trial (Bullen 2013) was based on absolute six month quit rates of
20% and 30% for the patch and nicotine EC groups respectively.
The effect size was estimated from themeta-analysis of NRT trials,
but the estimated patch group 20% quit rate, which was estimated
from previous research undertaken in New Zealand where partic-
ipants were recruited from among callers to the national Quitline,
was clearly too optimistic. The ASCEND study recruited directly
from the community and this population may not have been as
committed to quitting, or the national Quitline data were based
on a less rigorous standard (e.g. unvalidated self-reported absti-
nence rate). The ECLAT trial (Caponnetto 2013a) also overesti-
mated expected abstinence rates and the subsequent sample size
(n = 300) was insufficient to detect significant differences.
The cohort studies that we included were all deemed to have high
risks of bias, which is inherent in the study design. Some studies did
not define abstinence outcomes or validated self-reported smoking
status, which further lowers our confidence in the findings. Data
presented from these studies therefore needs to be interpreted with
caution.
A major limitation common to several cohort studies (e.g. Choi
2014; Dutra 2014; Lee 2014; Popova 2013) is the definition of
EC use, which is generally categorized as ‘ever use’ (e.g. ever tried,
even just once) and ‘current’ use (used on at least one day in the last
30 days). ’Ever use’ identifies experimentation, but oddly exper-
imentation within the last 30 days would be captured as current
use. Most of these studies were also unclear on the reasons for EC
use (e.g. as part of a quit attempt, trying the new product out of
curiosity, or to use when they cannot smoke) and failed to take
into account other relevant factors (e.g. level of dependence) in
their analyses. Perhaps most importantly, these studies excluded
EC users who stopped smoking and so only followed up ‘treat-
ment failures’. As such, causation cannot be inferred. As higher-
quality data become available, we will drop these studies from fu-
ture versions of this review.
Potential biases in the review process
We consider the review process used to be robust, and do not be-
lieve we have introduced any biases. For outcome assessment, we
followed the standard methods used for Cochrane Tobacco Ad-
diction Review Group cessation reviews. Our search strategy in-
cluded the Cochrane Tobacco Addiction Group Specialised Reg-
ister and we were able to capture a number of ongoing studies.
However, there may be unpublished data that our searches did
not uncover. We also considered participants lost to follow-up as
smokers, which is best practice in this field of work.
Agreements and disagreements with other
studies or reviews
When this review was initially published (McRobbie 2014), it was
the first review of ECs to pool data and conduct a meta-analysis.
Since then, 14 systematic reviews of EC safety and/or efficacy for
smoking cessation have been conducted (see Appendix 2). Three
of these present meta-analyses for smoking cessation, and of these,
two included the same studies that we include: Rahman 2015a,
which had virtually identical results to ours (RR 2.29. 95% CI
1.05 to 4.97), and Khoudigian 2016, which had similar results
but marginally missed statistical significance as they included six-
as opposed to 12-month data from Caponnetto 2013a, in which
the quit rate was slightly higher in the control group at six months
than at 12 months (RR 2.02, 95% CI 0.97 to 4.22). The third
meta-analysis, conducted by Kalkhoren and Glantz (Kalkhoran
2016), has significantly different results from ours, concluding
that, as currently being used, ECs are associated with significantly
less quitting among smokers (OR 0.72, 95% CI 0.57 to 0.91).
This review has generated considerable media attention and con-
troversy within the academic community (Hajek 2016). The cru-
cial difference between Kalkhoran’s meta-analysis and the other
three meta-analyses is that, rather than restricting the analysis to
include RCTs only, the authors have included a range of study
types, including cohort studies and cross-sectional studies, as well
as the two RCTs included in the other meta-analyses. Kalkhoran
and Glantz argue that the range of study types included in their
meta-analysis does not affect the validity of the result, as a sensi-
tivity analysis by study type did not reveal a significant difference.
However, given the paucity of RCTs (the sensitivity analysis com-
pared 19 non-randomized studies to two RCTs), there is very low
power to detect any reasonable difference. This very low power
explains why, despite the fact that the ORs for the RCTs and other
trials were in opposite directions (0.67 versus 1.38), the compari-
son was not statistically significant.
There are various reasons why RCTs provide different answers
from many observational studies in this area. These include varia-
tions in the effectiveness of ECs depending on the level of support
provided, issues around definitions of baseline EC usage, and un-
explored confounders. This is not an issue specific to ECs: cohort
studies of NRT show clear evidence that failure to adjust for con-
founders leads to estimates that suggest NRT is ineffective, while
including adjustment for variables related to tobacco dependence
supports its effectiveness (West 2007). In addition, those studies
which analyze results in smokers based on EC use at baseline have
by the nature of their design already excluded people who have
successfully quit using EC, and therefore only retain participants
who, at entrance to the study, would be classed as ’treatment fail-
ures’ or are in the midst of a cessation attempt involving cutting
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down to quit. Following the standard methods of the Cochrane
Tobacco Addiction Group and the protocol for this review, we
focused on evidence from randomized controlled trials for cessa-
tion outcomes, although we also analyzed cohort studies which
provided interpretable data.
Despite their differences, the one area in which all systematic re-
views of ECs for smoking cessation agree is that more evidence
is needed. The majority of recent systematic reviews in this area
sound a note of cautious optimism when it comes to the use of EC
as a smoking cessation aid, but the evidence base is limited, par-
ticularly in comparison with smoking cessation treatments with
established efficacy, such as traditional forms of nicotine replace-
ment therapy, varenicline and bupropion (Cahill 2016). Uncer-
tainty remains as to the long-term safety profile of ECs, given their
relatively new position in the market. Expert consensus broadly
holds that, based on all available evidence, ECs are considerably
safer than traditional cigarettes (McNeill 2015; RCP 2016), but
further studies are needed to establish their safety profile compared
with established smoking cessation aids.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A limited number of randomized trials have been reported, so cer-
tainty about the effects is low. More data are needed to strengthen
confidence in the estimates. There is evidence from the pooled
results of two trials that electronic cigarettes (ECs) with nicotine,
compared with placebo ECs, helped smokers to stop smoking
long-term. This corresponds to findings from placebo-controlled
trials of NRT (Stead 2012).
There is evidence from one trial that ECs may lead to six-month
quit rates similar to those achieved with NRT, but the confidence
interval is wide. ECs are an evolving technology and the effects of
newer devices with better nicotine delivery are unknown.
None of the included studies (short- to mid-term, up to two years)
detected serious adverse events considered possibly related to EC
use. Themost commonly reported adverse effects were irritation of
themouth and throat. The long-term safety of ECs is unknown. In
some studies, reductions in biomarkers were observed in smokers
who switched to vaping consistentwith reductions seen in smoking
cessation.
Implications for research
Although the gold standard in examining the efficacy ofmedicines,
including those used to help people stop smoking, is to com-
pare active treatment with placebo, testing ECs containing nico-
tine against ECs without nicotine presents a rather conservative
paradigm. This is because ECs provide nicotine replacement as
well as behavioural and sensory replacement for cigarettes. As both
of these elements are likely to be active ingredients of EC effects,
‘placebo-controlled’ trials are in effect subtracting the sensorimo-
tor element from EC efficacy. Although these sensorimotor effects
may be important to many smokers, we do not know how much
they might enhance quit rates. Existing evidence suggests that this
may be only small (Bullen 2013; Przulj 2013). Although placebo
ECs were important in testing ECs with metrics used in evalu-
ating NRT products, future studies should focus on comparing
ECs with ‘usual care’ or minimal treatment, and with alternative
pharmacological and behavioural treatments. In this update, we
found 15 ongoing RCTs with follow-up of six months or longer,
which include comparisonswith pharmacological and behavioural
treatments and ’usual care.’
Data are also needed on the proportions of smokers who success-
fully quit smoking with the help of ECs and who continue to use
ECs long-term, and the proportion who eventually become nico-
tine-free. To assess the effects of ECs on smokers at the popula-
tion level, data are needed on relationships between trajectories of
vaping and smoking rates in countries where both products are
available.
Given the variety of EC products on the market and the product
evolution, future studies need to select ECs with good nicotine
delivery that are representative of the best current standard in terms
of reliability and user satisfaction.
Further RCTs also need to be adequately powered, and to consider
providing ECs in a way that would be used in real-world settings
(e.g. taking into account individual preferences for strengths and
flavours of e-liquids and even EC devices).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adriaens 2014
Methods Design: 3-armed RCT (but for abstinence outcomes, treated as cohort in this review)
Recruitment: Advertisement on university website, flyers on university campuses, emails
to personnel and advertisement in local newspaper
Setting: Community and laboratory, Belgium
Inclusion criteria: Smoker for at least 3 years, smoking at least 10 factory-made cpd, not
intending to quit in the near future but willing to try a less unhealthy alternative
Exclusion criteria: Diabetes, severe allergies, asthma or other respiratory diseases, psychi-
atric problems, dependence on chemicals other than nicotine, pregnancy, breast feeding,
hypertension, CV disease, currently using any kind of smoking cessation therapy, prior
use of EC
Participants Total N: 48 provided data (51 consented, 50 attended any lab sessions, 2 further with-
drawals) Randomized to: EC1 16, EC2 17, control 17
56% women, mean age 44, mean cpd 19, mean FTCD 5.79, all unwilling to quit with
no baseline EC use
Interventions Intervention: 2 intervention groups (EC1 and EC2) provided with 2nd-generation EC
and instructed to use EC or smoke ad libitum (EC1 group provided with Joyetech eGO-
C, EC2 group provided with Kanger T2-CC) and provided guidance on EC use. For
both types, provided 30 mL bottles of tobacco-flavoured e-liquid (Dekang “Turkish
Blend”), containing 18 mg/mL of nicotine. 4 bottles at baseline replenished at 4 weeks,
keep any remaining after 8 weeks
Control: 6 bottles for 2 months at week 8 (half offered EC1, half offered EC2); no
guidance on use
Outcomes 3 lab sessions over 2 months (weeks 1, 4 and 8), plus online questionnaires, further
follow-up at 3 and 6m after last lab session
Cessation: measured but definition not provided, validated with eCO 5 ppm or less
Adverse events and biomarkers: eCO, salivary cotinine measured during lab sessions.
Also collected “complaints” via online diaries, not EC-specific
Also collected craving and withdrawal symptoms via lab sessions, “benefits and com-
plaints”, mood, EC usage
Notes Not included in cessation meta-analysis or interpreted as RCTs as does not meet our
inclusion criteria for RCTs (6m comparison with non-users/placebo). Reported narra-
tively alongside cohort studies. At 2 months, before the control group received EC, CO-
validated quit rates were 34% vs 0%
Risk of bias
Bias Authors’ judgement Support for judgement
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Adriaens 2014 (Continued)
Random sequence generation (selection
bias)
Low risk Block randomization was performed by us-
ing a randomization tool available on the
website www.randomizer.org
(But high for abstinence outcome as non-
randomized for our purposes)
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unblinded but as this review only includes
data on objective measurements and not
cessation judged unlikely to affect out-
comes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unblinded but as this review only includes
data on objective measurements and not
cessation judged unlikely to affect out-
comes
Incomplete outcome data (attrition bias)
All outcomes
Low risk 36 out of 48 completed follow-up (11/16
in EC1 group, 12/17 in EC2 group, 13/17
in control group)
Selective reporting (reporting bias) Unclear risk Outcome reporting somewhat non-tradi-
tional; for example, collecting complaints
but not explicitly adverse events, and inci-
dence of AEs not reported. Unable to find
prospectively registered protocol
Al-Delaimy 2015
Methods Design: Prospective cohort study
Recruitment: Members of California Smokers Cohort (longitudinal survey), recruited
proactively 2011 - 2013 via telephone
Setting: California, USA
Inclusion criteria: state residents aged 18 - 59 who had smoked at least 100 cigarettes
during their lifetime and smoked cigarettes “at least some days” at baseline
Exclusion criteria: Not stated
Participants Total N: 1000 adult smokers (for this review, only include 236 ever EC users and 306
’will never use EC’ respondents)
52.2% women; 30% 18 - 44 years old, 70% 45 - 59; 10% Hispanic, 73% non-Hispanic
white, 18% other; 83.6% daily smoker, 43% intended to quit smoking in next 6m
Interventions Observational, no specific intervention. At baseline asked to indicate if they had used,
might use, or would never use EC. Defined EC as “devices that look like cigarettes and
contain nicotine but do not produce tobacco smoke; some brands are The Safe Cig,
Green Smoke, and Blu.”
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Al-Delaimy 2015 (Continued)
Outcomes Self-reported prolonged abstinence for 1m or longer, assessed via phone at 12m
Also measured quit attempts, reduction
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Observational study
Allocation concealment (selection bias) High risk Observational study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although there is no blinding, the study
design and lack of intervention or contact
with researchersmean that there is unlikely
to be significantly impact on performance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Telephone report, unblinded, but given
nature of the study differential misreport
seems unlikely
Incomplete outcome data (attrition bias)
All outcomes
High risk Greater loss to follow-up for ’will never use’
than users
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
Borderud 2014
Methods Design: Prospective observational cohort study
Recruitment: Patients presenting with cancer at large US cancer centre; smokers referred
to tobacco cessation programme (TCP). This study included all patients who completed
TCP intake assessment, 2012 - 2013
Setting: Cancer centre, USA
Inclusion criteria: Smokers (smoked cigarettes or used other tobacco products within
past 30 days) accepting cessation programme
Exclusion criteria: none stated
Participants Total N: 1074. 781 eligible for 6 - 12m follow-up
56.5% women, mean age 56, mean cpd 13, mean FTND 3.7. At baseline, 26.5% (285/
1074) had used EC within last 30 days, 92% dual users
Interventions All participants offered ”multicomponent, evidence-based behavioral and pharmacologic
treatment for tobacco dependence”; plans differed by individual but offered up to 5
sessions of phone or in-person counselling
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Borderud 2014 (Continued)
Outcomes Follow-up ranged from 6 to 12m after enrolling in TCP (mean 10m). Collected:
Self-reported 7-day PP abstinence
Gone at least 1 day without smoking
CPD
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Observational
Allocation concealment (selection bias) High risk Observational
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although there is no blinding, the study
design means that there is unlikely to be
significantly impact on performance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Self-report only but differential misreport
across EC conditions judged to be unlikely
Incomplete outcome data (attrition bias)
All outcomes
High risk Large number of participants (285) lost to
follow-up (of eligible, 59.5% followed up).
A further 82 deceased “significantly higher
percentage of E-cigarette users dropped out
of tobacco treatment and were lost to fol-
low-up than non-E-cigarette users”. Com-
plete-case analysis not significant, ITT
analysis significant
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
Brose 2015
Methods Design: Prospective cohort study
Recruitment: National general population sample recruited from online market research
organization, 2012 - 2013
Setting: web-based, UK
Inclusion criteria: Smoked in the past year
Exclusion criteria: not stated
Participants Total N: 4064, 1769 followed up
50%women,mean age 43.4,mean cpd 12.9, 23%used EC at baseline, 46.3% attempted
to quit in past year
Of those using EC at baseline, majority used ‘first generation’ EC that were cigarette-
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like in appearance
(‘cigalikes’)
Interventions None
Outcomes Reported being ’ex-smoker’ at 12m follow-up
Quit attempts
50% reduction in cpd
Notes Baseline characteristics fromBrown 2014a, but reports broader sample than that included
here so some characteristics may be different from those reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Observational study
Allocation concealment (selection bias) High risk Observational study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although there is no blinding, the study
design and lack of intervention or contact
with researchersmean that there is unlikely
to be significantly impact on performance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Online survey, differential misreport seems
unlikely
Incomplete outcome data (attrition bias)
All outcomes
High risk 43.3% (1759) followed up. 1687 used in
analyses due to missing data or baseline
pipe or cigar smoking. 1473 used in quit
attempt analysis (further missing data)
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
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Methods Design: 3 parallel groups RCT
Recruitment: Smokers recruited from the community, via newspaper advertisements
Setting: Research Unit, New Zealand
Inclusion criteria: 18 years of age or older; Smoked 10 ormore cpd over past year;Wanted
to stop smoking
Exclusion criteria: pregnant and breastfeeding women, people using cessation medicines
or using other support to quit, heart attack, stroke, severe angina in the last 2 weeks,
poorly-controlled medical disorder, allergies, other chemical dependence
Participants Total N: 657
62% women, mean age 42, NZ Maori, smoking 18 cpd, mean FTND score 5.5
Lost to follow-up at 6 months:
• NEC (nicotine EC): 43/289
• PATCH: 58/295
• PEC (placebo EC): 15/73
Discontinued treatment:
• NEC: 4/289
• PATCH: 22/295
• PEC: 1/73
Interventions Randomized 4:4:1 to NEC, PATCH or PEC use for 13 weeks (from 1 week prior to
TQD)
• NEC: Elusion brand 16 mg cartridges; sent product via courier
• PATCH: 21 mg/24-hour patch; sent voucher to exchange for NRT at pharmacy
(dispensing costs covered)
• PEC: As per EC but 0 mg cartridges
All participants referred to Quitline and received an invitation to access phone- or text-
based support. This was accessed by < 10%
Outcomes Sustained (≤ 5 cigarettes allowed) validated (exhaled breath CO < 10 ppm) abstinence
at 6 months
≥ 50% self-reported reduction in baseline cigarettes at 6 months
Participants reporting any adverse events
Proportion of AEs that were serious
Proportion of unrelated AEs
Notes Accessed support: NEC: 115/289; PATCH: 106/295; PEC: 26/73
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised block randomization
Allocation concealment (selection bias) Low risk Computerised via study statistician
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk NEC and PEC were blind to treatment
condition in relation to one another. No
blinding for NEC/PEC vs PATCH condi-
tions, but as NEC and PATCH were both
active treatments performance bias judged
unlikely
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemical validation used
Incomplete outcome data (attrition bias)
All outcomes
Low risk LTFU 22% (all considered smokers). Patch
group had a higher LTFU and withdrawal
than EC (loss to follow-up 17% NEC,
27% patches, 22% PEC). However, min-
imal difference in per-protocol and ITT
analyses
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Caponnetto 2013a
Methods Design: 3-arm double-blind randomized controlled trial: EC with 7.2 mg nicotine for
12 weeks; same for 6 weeks followed by 5.2 mg for 6 weeks: EC with no nicotine for 12
weeks
Recruitment: Newspaper advertisements
Setting: Outpatient clinic, Italy
Inclusion criteria: Smoked at least 10 cpd for past 5 years; age 18 - 70; in good health;
not currently or intending to quit smoking in the next 30 days
Exclusion criteria: symptomatic cardiovascular or respiratory disease; regular psy-
chotropicmedicine use; current or past history of alcohol abuse; use of smokeless tobacco
or NRT; pregnant or breast feeding
Participants Total N: 300
36% women, mean age 44 (SD 12.5), mean cpd 20 (IQR: 15 - 25)
Lost to follow-up at 12 months
• Grp A: N = 35/100
• Grp B: N = 37/100
• Grp C: N = 45/100
No participants discontinued intervention
Interventions EC presented as a healthier alternative to tobacco smoke and could be freely used, ad
libitum (up to 4 cartridges per day) for 12 weeks, as a tobacco substitute
EC used: ’Categoria’ (model 401) with disposable cartridges
• Grp A: 12 weeks of 7.2 mg capsules (’Original’)
• Grp B: 6 weeks 7.2 mg (’Original’) then 6 weeks 5.4 mg (’Categoria’)
• Grp C: 12 weeks of 0 mg (’Original’)
Baseline visit and up to 7 follow-up visits to receive more cartridges, hand in diaries,
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measure CO and vital signs
Outcomes Abstinence at 12months (complete self-reported abstinence from tobacco smoking since
previous visit at 6 months, confirmed with CO < 7 ppm at 12 months)
≥ 50% reduction in baseline cigarettes at 12 months
Recorded AEs thought to be related to tobacco smoking and EC at baseline and at each
study visit (7 follow-up visits over 12 weeks, plus at 24 and 52 weeks)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, block size 15 (5:5:5
ratio)
Allocation concealment (selection bias) Low risk Randomization carried out by pharmacy,
who did not have direct contact with the
participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. “Blinding was ensured by
the identical external appearance of the
cartridges. The hospital pharmacy was in
charge of randomization and packaging of
the cigarettes”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemical validation used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 211 (70.3%) and 183 (61%) attended 6-
and12-month follow-up (at 12m, 35% lost
in 7.2 group; 37% lost in 5.4 group; 45%
lost in no-nicotine group)
Selective reporting (reporting bias) Unclear risk Unclear if original intention was to com-
bine groups A+B or not. In sample size cal-
culation they compared A+B with C, but
results are not reported in this way
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Methods Design: Prospective cohort
Recruitment: Inpatients at a psychiatric institution in Italy
Inclusion criteria: Smoked≥ 20 cpd for at least the past 10 years; diagnosis of schizophre-
nia
Exclusion criteria: Alcohol and illicit drug use, recent myocardial infarction, angina
pectoris, high blood pressure (BP > 140 mmHg systolic or 90 mmHg diastolic, or both)
, diabetes mellitus, severe allergies, poorly-controlled asthma or other airway diseases
Participants Total N: 14
57% women, mean age 44.6 (SD 12.5), mean pack years smoked 28.8 (SD 12.9)
Interventions Seen at baseline, given EC (’Categoria’ brand) with an initial 4-week supply of 7.4 mg
nicotine cartridges. Instructed to use ad libitum up to 4 cartridges per day. EC cartridges
supplied at months 1, 2, and 3
No instruction on cessation or reduction was provided.
Outcomes Follow-up at 1, 2, 3, 6 and 12 months where cigarette consumption, CO, AEs and
positive and negative symptoms of schizophrenia were measured
Sustained reduction of ≥ 50% for at least 30 days at 12 months
30-day point prevalence CO-validated abstinence at 12 months
Adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Prospective cohort; no randomization
Allocation concealment (selection bias) High risk Not randomized
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemical validation used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0/14 lost to follow-up
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
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Methods Design: Longitudinal survey (data from theMinnesota Adolescent Community Cohort)
Recruitment: Participants selected via cluster random sampling of household phone
numbers
Setting: Telephone survey
Inclusion criteria: Participants who completed the survey between October 2010 and
March 2011 and provided follow-up data 1 year later
Exclusion criteria: none stated
Participants Total N: 346
Interventions Observational; no specific intervention. No data on nicotine content of ECs are provided
Outcomes Self-reported smoking cessation at 1-year follow-up (not otherwise defined)
Notes This publication is a letter in response to a comment on the authors’ original paper Choi
2014, and the details on methods are taken from this.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Prospective cohort
Allocation concealment (selection bias) High risk Not randomized
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although there is no blinding, the study
design and lack of intervention or contact
with researchersmean that there is unlikely
to be significantly impact on performance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Although there is no blinding, the study
design and lack of intervention or contact
with researchersmean that there is unlikely
to be significantly impact on detection
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unable to determine attrition bias
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
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Methods Design: Prospective cohort
Recruitment: Letter sent to family practice patients who were current smokers
Setting: Single family practice, Colorado USA
Inclusion criteria: Want to quit or switch from tobacco cigarettes to ECs
Exclusion criteria: None reported
Participants Letters sent to 640 patients, 48 chose to participate and 44 completed the programme,
4 were lost to follow-up
Of the 44 participants, 66% women, all non-Hispanic/white, aged 20 - 75 (30% were
age 51 - 60), 57% had a high school education or less
Interventions The 6-month smoking cessation programme was based on The ’5 A’s’ model and trans-
theoretical model. Options for treatment were discussed with each participant at the start
of the programme. All used an EC, with 16 using bupropion and 2 using varenicline as
well
Participants were provided with written information on “blu cig” and “smoke tip” ECs,
regarding cost, availability, nicotine dosage options
Outcomes Phone follow-ups at 2 weeks, 1 month, 3 months, and 6 months
At completion of programme (using ITT)
Abstinence from smoking and EC use
Abstinence from smoking but not EC use
≥ 50% reduction of baseline cigarette consumption (still using ECs)
Notes No definition of abstinence provided
Not clear if ’completed programme’ was at 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Prospective cohort
Allocation concealment (selection bias) High risk Not randomized
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/48 lost to follow-up
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
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Other bias High risk No definition of abstinence provided
Not clear if ’completed programme’ was at
6 months.
Etter 2014
Methods Design: Longitudinal Internet survey
Recruitment: Via websites selling or informing about ECs and online EC forums
Setting: Online survey (open to all nationalities; of respondents, 34% US, 24% France,
8% UK, 6% Switzerland, 28% other countries)
Inclusion criteria: Aged 18 years and older
Exclusion criteria: none stated
Participants One-month survey
Total N: 477, mean age 42, 41% women, 59% had a diploma giving access to university,
28%daily or occasional smokers, 76%daily ECusers. 50/477 occasional or daily smokers
at baseline
One-year survey
Total N: 367, mean age 43, 42% women, 59% had a diploma giving access to university,
24%daily or occasional smokers, 79%daily ECusers. 35/367 occasional or daily smokers
at baseline
Interventions Observational; no specific intervention. Participants that had completed a baseline ques-
tionnaire were emailed one month and one year later and asked to provide follow-up
data on EC use and smoking behaviour
Outcomes From among those that were smoking cigarettes at baseline
7-day PP abstinence from smoking at 12 months
Smoking consumption (change from baseline) at 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Prospective cohort
Allocation concealment (selection bias) High risk Not randomized
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although there is no blinding, the study
design and lack of intervention or contact
with researchersmean that there is unlikely
to be significantly impact on performance
45Electronic cigarettes for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Etter 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Although there is no blinding, the study
design and lack of intervention or contact
with researchersmean that there is unlikely
to be significantly impact on detection
Incomplete outcome data (attrition bias)
All outcomes
High risk 28% (N = 367) for those who answered the
baseline survey (N = 1329) provided data
at 1-year follow-up
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
Grana 2014b
Methods Design: Longitudinal web-based survey
Recruitment: Via Knowledge Networks (nowGfK) probability-based web-enabled panel
Setting: Web-based survey, USA
Inclusion criteria: Aged 18 years and older
Exclusion criteria: none stated
Participants Total N: 949
52.4% women, 90.8% having at least a high school education, 75.3% white, mean (SD)
daily cigarette consumption 14.5 (9.7), 59% smoke within 30 minutes of waking, 69.
4% never expecting to quit or intending to quit in the next 6 months
90.7% did not use (EC use within the last 30 days) an EC at baseline. No data on
nicotine content of EC are provided
Interventions Observational; no specific intervention
Outcomes Self-reported smoking cessation at 1-year follow-up (not otherwise defined)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Prospective cohort
Allocation concealment (selection bias) High risk Not randomized
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although there is no blinding, the study
design and lack of intervention or contact
with researchersmean that there is unlikely
to be significantly impact on performance
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Although there is no blinding, the study
design and lack of intervention or contact
with researchersmean that there is unlikely
to be significantly impact on detection
Incomplete outcome data (attrition bias)
All outcomes
Low risk 81.3%of the participants of baseline survey
completed follow-up survey
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
Hajek 2015a
Methods Design: Prospective cohort, intervention provided
Recruitment: Smokers attending stop-smoking service
Setting: Stop-smoking service, London, UK
Inclusion criteria: All smokers joining stop-smoking service
Participants Total N: 100 (69 of whom accepted offer of EC)
38% women (those who accepted) 55% women (those who declined), mean age 41,
mean cpd 14, all motivated to quit. EC use at baseline not specified but some who
declined EC offer had used EC in the past
Interventions EC: offered to all smokers joining service; offered choice of ‘cigalike’ (Gamucci, 1.6% or
2.2% nicotine per ml) product or tank model (EVOD, 1.8%; later replaced with Aspire
product due to leakage issues). 69% of those offered received an EC on TQD
Medication: Offered stop-smoking medications including NRT and varenicline as in
standard protocol. Of EC users 33% opted to also use NRT, 29% varenicline, 38%
nothing
Support: weekly, as in standard protocol
Outcomes Adverse events collected throughout, method for collection unclear
Also collected: 4-week biochemically-validated abstinence, client feedback, cost
Notes Study allows a comparison between users and non-users of EC but follow-up only 4
weeks so does not contribute to abstinence results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not randomized
Allocation concealment (selection bias) High risk Not randomized
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Unblinded but given nature of the study
judged unlikely to affect results
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unblinded but given nature of the study
judged unlikely to affect results
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 26% lost in EC group, dropout rate in EC
decliners not reported. Reasons for dropout
not stated
Selective reporting (reporting bias) Unclear risk Unclear which outcomes authors set out to
collect, no protocol available
Humair 2014
Methods Design: Prospective cohort
Recruitment: People attending an outpatient clinic
Setting: University hospital outpatient clinic, Switzerland
Inclusion criteria: Wish to reduce tobacco use or had failed to stop smoking using
varenicline, bupropion or NRT in past
Participants TOTAL N: 17
mean 23 cpd, 82% had a psychiatric illness
Interventions Offered an EC with nicotine
59% also reported using NRT or varenicline in addition to EC
Outcomes Smoking cessation and reduction by at least 30% at 12 months (self-report)
Adverse events
No significant side effects
Notes Abstract only, hence little detail available
Not clear if EC was provided by clinic or if participants had to buy their own
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Prospective cohort
Allocation concealment (selection bias) High risk Not randomized
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding, no biochemical validation
used
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers lost to follow-up not reported
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
Manzoli 2015
Methods Design: Prospective cohort study
Recruitment: Community, Abruzzo, Italy
Setting: 2013, via GPs, EC shops, internet advertisements and social networks
Inclusion criteria: Adults (30 - 75 years), smokers of at least 1 tobacco cigarette/day
(tobacco smokers) for past 6m, users of any type of EC, inhaling at least 50 puffs weekly
for past 6m (e-smokers), or smokers of both tobacco and EC (smoked both tobacco and
EC within the same week for the past 6 months) (dual smokers)
Exclusion criteria: Age < 30 yrs and > 75 yrs; pregnancy or breastfeeding; illicit drug use,
major depression, severe allergies, angina, and past episodes of smoking-related major
diseases
Participants Total N: 1012 (includes only those smoking at baseline)
44.1% women, mean age 44.5, mean cpd 14.4
60% of EC users using to quit, 36.5% to reduce
Interventions Observational only, no intervention provided. Mean EC nicotine dose 9.8 mg, mean
EC daily puffs 130, mean months of EC use 8.6
Outcomes 12m (Planned also 24, 36, 60m - this is noted as early data)
30-day sustained abstinence, CO tested in 25% random sample of those declaring ab-
stinence
30-day abstinence from EC and tobacco
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Observational
Allocation concealment (selection bias) High risk Observational
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although there is no blinding, the study
design and lack of intervention or contact
with researchersmean that there is unlikely
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to be significantly impact on performance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk CO tested in 25% random sample of those
declaring abstinence. Of those, 4% misre-
port (2 tobacco smokers, 1 e cig user)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 70.8% response rate overall
Selective reporting (reporting bias) Low risk All expected outcomes reported. Authors
initially planned follow-up at 6m but fund-
ing was withdrawn
McRobbie 2015
Methods Design: Prospective cohort
Recruitment: advertisements in free London newspapers
Setting: Smokers’ clinic, East London, UK
Inclusion criteria: Daily smokers who want to quit, aged 18 and older
Exclusion criteria: pregnant and breastfeeding women, current serious medical illness,
EC use for more than 1 week in the past
Participants Total N: 40
45% women, mean age 47 (SD 12), mean cpd 19 (SD 10), mean FTND 5.2 (SD 2.8),
65% in full-time employment
Interventions Participants attended baseline session 1 week prior to their TQD. On the TQD, partic-
ipants were provided with an EC (Green Smoke, 1st generation device, 2.4% nicotine
cartridges). 2 cartridges per day were supplied initially, with the supply adjusted to ac-
tual use later. Attended 4 weekly follow-up sessions and received standard behavioural
support
Outcomes Cigarette consumption and CO readings collected at each session. Urine sample for
cotinine and 3-HPMA analysis collected at baseline and 4 weeks post-TQD
Change in urinary 3-HPMA (ng/mg creatinine) at 4 weeks
Change in urinary cotinine (ng/mg creatinine) at 4 weeks
Change in CO at 4 weeks
Notes Previously McRobbie 2014, ID updated in this version to reflect 2015 publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Prospective cohort
Allocation concealment (selection bias) High risk Not randomized
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemical validation used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7/40 participants were lost to follow-up
Selective reporting (reporting bias) Low risk All predefined outcomes reported
Nides 2014
Methods Design: Open-label non-comparative study
Setting: Clinical Trials Unit, USA
Recruitment: Study site database and community advertisements
Inclusion criteria: age 18 - 65 years; good health; BMI 18 - 35; smoking 10+ cpd; and
CO > 10 ppm
Exclusion criteria: pregnancy or breastfeeding; other drug dependency; use of any psy-
chiatric or opioid medications; EC within the previous 14 days; use of NRT in last 30
days; want to reduce or quit smoking within the next 30 days
Participants Total N: 29
44% women; mean age 43; mean cpd 20.1; mean FTND 4.5
Interventions Participants attended 3 clinic visits at 1-week intervals
Visit 1: Baseline
Visit 2: Provided with 1st generation type - ’NJOY®King Bold’ (NJOY, Inc., Scottsdale,
AZ), with 26 mg nicotine. Used ad libitum for 20 minutes in the clinic, then ad libitum
use over the next week. Recorded use of regular cigarettes and puffs on EC
Visit 3: Participants abstained from all sources of nicotine for 12 hours prior to visit
Outcomes Adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Prospective cohort
Allocation concealment (selection bias) High risk Not randomized
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemical validation used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants dropped out between visits
1 and 2.
Selective reporting (reporting bias) Low risk Planned comparisons reported
Oncken 2015
Methods Design: Randomized cross-over study
Recruitment: Newspaper advertisements, radio announcements, and from local general
medicine practices
Setting: Lab-based study, Connecticut, USA
Inclusion criteria: non-treatment-seeking smokers whowere willing to try EC for 2 weeks
and abstain
from conventional cigarette smoking. 18 - 55 years of age who smoked at least 10 cpd
Exclusion criteria: pregnant, previous myocardial infarction or stroke, uncontrolled hy-
pertension (blood pressure (BP) > 160/100), insulin-dependent diabetes, COPD or cur-
rent asthma, known allergy to propylene glycol
Participants Total N: 27
45% women; mean age 42; 70% white; 15% Hispanic, 15% black; mean cpd 16; 45%
had tried EC at baseline, 50% smoked menthol cigarettes
Interventions Prescribed Joye eGo-C (www.joyetech.com) and e-Juice (18 mg/mL nicotine) procured
fromAmerican eLiquid (www.americanliquid.com). Cross-over study betweenmenthol-
flavoured and non-menthol tobacco-flavoured EC. Requested not to smoke their regular
cigarettes during study period; howevermajority (60%) reported intermittently smoking
cigarettes during study
Outcomes Follow-up at 1w and 2w
BP, heart rate, body plethysmography, static lung volumes and airways resistance (Raw)
and specific conductance (sGaw) - taken at lab visits after abstaining from EC for at least
2 hrs, then taken again after inhaling EC and repeated 5 mins later
Adverse events also reported but method for measuring not stated
Also measured nicotine concentrations, rates of cigarette and EC use
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
52Electronic cigarettes for smoking cessation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Oncken 2015 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method not stated; “Subjects were then
randomly assigned to use the menthol or
plain e-cigarette cartridge for one week,
switching to the other cartridge for the sec-
ond week”
Allocation concealment (selection bias) Unclear risk No detail given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No detail given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No detail given
Incomplete outcome data (attrition bias)
All outcomes
Low risk 20/27 followed up
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
Pacifici 2015
Methods Design: Uncontrolled pre-post pilot study
Recruitment: Word of mouth
Setting: Hospital-based smoking cessation clinic, Italy
Inclusion criteria: Adult smokers unwilling to quit smoking tobacco cigarettes and who
have never tried a quit smoking protocol and/or have refused any smoking cessation
treatment
Exclusion criteria: none stated
Participants Total N: 34
47.1% women, mean age 40.6, mean cpd 21.5, no EC use at baseline, not motivated to
quit
Interventions EC:
Participants were given commercially available EC (AVATAR device, Battery 550 mAh/
3.9 V, W: 7.8, cartomizer with 2, 2 ohm resistance, tank capacity 1.5 mL, temperature
of the aerosol: 55/65 degrees), 2 different chargers for each EC and PUFFIT e-liquids
with nicotine content matching the individual nicotine daily intake and tobacco and/or
other flavours freely chosen by each participant
W1: nicotine-free e-liquid
W2&3: Own EC with personal nicotine dosage, encouraged to use as substitute for
traditional cigarettes
W4: Encouraged to forego all traditional cigarettes
Throughout: assistance at any time of day from centre staff with any EC-related problem,
plus follow-up group sessions and smartphone messaging application
Behavioural support:
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Multi-component medically-assisted training programme with monitoring of nicotine
intake as a biomarker of correct EC use, including Information about general working
principles, safety and risks of EC, together with medically-assisted face-to-face training
on how to correctly use the device to absorb nicotine vapour
Outcomes Follow-up at 1, 4 and 8m
Cessation (measure not defined)
Adverse events
Exhaled CO, COT, 3-HCOT concentration
cpd
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not controlled
Allocation concealment (selection bias) High risk Not controlled
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No detail provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if staff were blinded to partici-
pant EC usage, not clear how cessation was
defined
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants followed up
Selective reporting (reporting bias) High risk AEs measured but not reported
Polosa 2011
Methods Design: Prospective cohort
Recruitment: Advertisments in local hospital in Catania, Italy
Inclusion criteria: Healthy smokers 18 - 60 years old, smoking ≥ 15 cpd for at least the
past 10 years, and not wanting to quit smoking at any time in the next 30 days
Exclusion criteria: History of alcohol and illicit drug use, psychiatric illness, recent my-
ocardial infarction, angina pectoris, high blood pressure (BP > 140 mmHg systolic or 90
mmHg diastolic, or both), diabetes mellitus, severe allergies, poorly-controlled asthma
or other airways diseases
Participants Total N: 40, hospital staff
35% women, mean age 42.9 (SD 8.8), median cpd 25 (IQR 20 - 30), median FTND
6.0 (IQR 6 - 8)
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Interventions Seen at baseline, given EC (’Categoria’ brand) with an initial 4-week supply of 7.4 mg
nicotine cartridges. Instructed to use ad libitum up to 4 cartridges per day. EC cartridges
supplied at months 1, 2, and 3
No instruction on cessation or reduction was provided
Outcomes Follow-up at 1, 2, 3, 6, 18 and 24 months where cigarette consumption, CO, and AEs
were measured, incl. 30-day PP CO-validated abstinence at 6 months and CO-validated
abstinence at 18 & 24 months (not otherwise defined)
Adverse events
Notes Smoking cessation services provided to those who spontaneously asked for assistance
with quitting. These participants were excluded from the study protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Prospective cohort
Allocation concealment (selection bias) High risk Not randomized
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemical validation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 13/40 were lost to follow-up, but used ITT
analysis
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
Polosa 2014a
Methods Design: Retrospective cohort (retrospective audit of clinical records)
Recruitment: Review ofmedical records from a respiratory outpatient clinic in Italy from
September 2012 until December 2013
Setting: Respiratory outpatient clinic, Italy
Inclusion criteria: People with mild to moderate asthma reporting regular EC use on at
least 2 consecutive follow-up visits
Exclusion criteria: None reported
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Participants Total N: 18, 39% (N = 7) women
10 were using EC only (3 women, mean age 36)
8 used ECs and smoked ≤ 5 cpd (4 women, mean age 42)
Both groups smoked 22 cpd at baseline
Duration of EC use 10 - 14 months. N = 12 using them for > 1 year
All started on 1st generation EC, but the ’majority’ switched to a ’personal vaporiser’
(2nd or 3rd generation)
Interventions Observational; no specific intervention. First 2 observations prior to EC use, second 2
observations during EC use
Outcomes Data from 4 clinic visits were collected: (1) pre-baseline (6 - 12 months prior to baseline)
; (2) baseline; (3) 6 (± 1) month follow-up; and (4) 12 (± 2) month follow-up. Visits 1
and 2 were pre-EC use and visits 3 and 4 were during EC use
At each visit, participants were assessed by clinical history and examination and re-
evaluation of treatment adherence and efficacy
1. Juniper’s Asthma Control Questionnaire (ACQ) score
2. Number of exacerbations from the previous follow-up visit (defined as an increase
in respiratory symptoms requiring a short course of oral or parenteral corticosteroids)
3. Forced expiratory flow in 1 second (FEV1)
4. Forced vital capacity (FVC)
5. Expiratory ratio (% FEV1/FVC)
6. Forced expiratory flow at the middle half of the FVC (FEF 25 - 75%);
7. Bronchial provocation tests assessing Airway HyperResponsiveness (AHR) with
methacholine (some participants only)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Retrospective cohort
Allocation concealment (selection bias) High risk Self-selected sample
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although there is no blinding, the study
design and lack of intervention means that
there is unlikely to be significantly impact
on performance
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No biochemical validation undertaken
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not applicable; unclear if some participants
attendedfirst 3 visits but not 4th, andhence
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were excluded
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
Polosa 2014b
Methods Design: Prospective cohort study
Recruitment: Volunteers, leaflets, cessation service kiosk in hospital
Setting: Smoking cessation clinic, Italy
Inclusion criteria: Healthy smokers 18 - 60 years old, smoking ≥ 15 conventional cpd
for at least 10 years, unwilling to quit
Exclusion criteria: none stated
Participants Total N: 50
40% women, mean age 41, mean cpd 25, mean FTND 6.0, no EC use at baseline, not
motivated to quit
Interventions EC:
2nd generation devices (personal vaporisers - PVs): EGO/CE4model, filledwith tobacco
aroma e-Liquid containing 9 mg/ml nicotine; instructed to use the study products ad
libitum (up to a maximum of 5 ml/day; i.e. half vial)
Behavioural support:
Participants were instructed how to charge, fill, activate and use the EC. Key trou-
bleshooting was addressed and phone numbers were supplied for assistance. “No empha-
sis on encouragement, motivation and reward for the smoking cessation-related efforts
were provided during the study.”
Outcomes 4, 8, 12 and 24w
30-day PP verified by CO ≤ 10 ppm
Adverse events
Cpd, exhaled CO, reduction rates, product usage, and opinions of the EC products
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not controlled
Allocation concealment (selection bias) High risk Not controlled
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically-verified abstinence, adverse
events collected through study diaries
Incomplete outcome data (attrition bias)
All outcomes
Low risk 76% followed up, ITT analysis used, no
significant differences in baseline character-
istics between completers and those lost to
follow-up
Selective reporting (reporting bias) Low risk Unable to determine prespecified outcomes
Polosa 2015
Methods Design: Prospective cohort
Recruitment: Professional retail staff in participating vape shops
Setting: 7 vape shops in Catania province, Italy
Inclusion criteria: Adult smokers (≥ 18) making first purchase at participating vape shop
(definition of smoker not stated)
Exclusion criteria: none stated
Participants Total N: 71
38% women, mean age 41.7, mean cpd 24.9, mean FTND 5, no EC use at baseline
Interventions Instructed how to charge, fill, activate and use EC; key troubleshooting advice provided;
phone number available for technical support. “Encouraged to use these products in
anticipation of reducing the number of cig/day smoked”
Outcomes 6 and 12m follow-up
30-day PP abstinence via self-report
Details of product purchase
Sustained 50% and 80% reduction in cpd from baseline
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not controlled
Allocation concealment (selection bias) High risk Not controlled
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clear howfinal follow-upmeasures col-
lected
Incomplete outcome data (attrition bias)
All outcomes
Low risk 69% follow-up at 12m. Participants lost to
follow-up considered as continuing smok-
ers
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
Prochaska 2014
Methods Design: Prospective observational study using data from a 3-group randomized RCT
Recruitment: 2009 - 2013, recruited as part of clinical trial of smokers with serious
mental illness
Setting: Inpatient psychiatric hospital, California, USA
Inclusion criteria: Daily smokers of 5+ cpd, patient at 100% smoke-free acute care unit
at psychiatric hospitals
Exclusion criteria: non-English speaking; medical contraindications to NRT use (preg-
nancy, recent myocardial infarction); and lack of capacity to consent as determined by a
3-item screener of study purpose, risks, and benefits
Participants Total N: 956
• UC 134
• Brief treatment 414
• Extended treatment 408
50% women; mean age 39; 15% Hispanic, 57% white, 24% African-American, 5%
Asian/Pacific Islander; 14% multiracial/other; mean cpd 17; 11% used EC at baseline,
24% intended to quit smoking in next month
Psychiatric diagnoses were 27% unipolar depression, 32% bipolar depression, and 27%
nonaffective psychotic disorder; other (14%). 68% met criteria for alcohol or illicit drug
abuse or dependence
Interventions RCT tested levels of behavioural support:
Usual care; brief treatment; extended treatment. Treatment groups received tailored com-
puter-assisted intervention or on-unit counselling. Extended group offered 10 sessions
of CBT
No significant differences in EC use by treatment group. All participants were provided
NRT following hospitalization (3 months brief arm, 6 months extended arm)
Outcomes Follow-up at 3, 6, 12, 18m. This paper reports “latest follow-up”
Cessation measured but definition not described
Cpd
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Observational for purpose of this analysis
Allocation concealment (selection bias) High risk Observational for purpose of this analysis
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although there is no blinding, the study
design means that there is unlikely to be
significantly impact on performance by EC
use at baseline
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clear how outcome measures were as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Follow-up for larger RCT still ongoing, un-
clear what percentage of participants eligi-
ble for this analysis were followed up
Selective reporting (reporting bias) Low risk All expected outcomes reported
Van Staden 2013
Methods Design: Single-group within-subject design
Recruitment: Participants from a military hospital in South Africa
Inclusion criteria: Adult daily smokers of at least 10 cpd
Exclusion criteria: History of lung disease
Participants Total N: 15, mean age 38 years, smoked 20 cpd (range 10 - 30), for an average of 17
years (range 5 - 27)
Total N: 13 completed the study (5 women)
Interventions Participants were asked to use an EC only for 2 weeks (i.e. no cigarettes)
EC: ’Twisp eGo’ cartridge 0.8 ml containing 0.0144 mg of nicotine
Outcomes The following measurements were taken at baseline and 2-week follow-up:
1. Blood pressure and pulse
2. Arterial and venous COHb and blood oxygen saturation
Notes Dropouts (N = 2) were due to illness (headache and fever) and undertaking a military
course associated with high stress and exposure to others smoking, making it difficult to
abstain from cigarettes
The paper states that the EC cartridge contained 0.8 ml of solution with 0.0144 mg
of nicotine. This would be an unusually low concentration of nicotine and we have
assumed an error in units where milligrams should have been grams (0.0144 grams of
nicotine would make the concentration 18 mg/ml)
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Prospective cohort
Allocation concealment (selection bias) High risk Not randomized
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/15 lost to follow-up
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes
AE: adverse event
BMI: body mass index
CO: carbon monoxide
COT: cotinine
cpd: cigarettes per day
EC: electronic cigarette
FTND: Fagerström Test for Nicotine Dependence
IQR: interquartile range
ITT: intention-to-treat
LTFU: lost to follow-up
NEC: nicotine electronic cigarette
NRT: nicotine replacement therapy
PEC: placebo electronic cigarette
PP: point prevalence
SAE: serious adverse event
SD: standard deviation
TQD: target quit date
UC: usual care
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adkison 2013 Although this study uses a prospective cohort design, no data on EC use were collected at baseline, with EC use
data only being available at follow-up
Battista 2013 Short-term EC use only
Biener 2015 Cohort study, but EC use evaluated retrospectively only
Brown 2014a Cross-sectional survey
Bullen 2010 Short-term EC use only
Chausse 2015 Ineligible study design
Chorti 2012 Short-term EC use only
Czogala 2012 Short-term EC use only
Dawkins 2012 Short-term EC use only
Dawkins 2013a Short-term EC use only
Dawkins 2014 Short-term EC use only
Douptcheva 2013 Longitudinal study, but no data are reported for smoking cessation or reduction or for adverse events
Dutra 2014 Cross-sectional survey
Eissenberg 2010 Short-term EC use only
Farsalinos 2012 Short-term EC use only
Farsalinos 2013a Included people that had already stopped smoking conventional cigarettes
Farsalinos 2013b Short-term EC use only
Farsalinos 2013c Short-term EC use only
Farsalinos 2013d Short-term EC use only
Flouris 2012 Short-term EC use only
Flouris 2013 Short-term EC use only
Gmel 2016 Cohort study, but EC use only evaluated retrospectively
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James 2016 Follow-up at 12 weeks, AE data not collected
Kasza 2013 Longitudinal study, but no data are reported for smoking cessation or reduction or for adverse events
Kouretas 2012 Short-term EC use only
Lee 2014 Cross-sectional survey
Marini 2014 Short-term EC use only
Miura 2015 Tests a device which is not an EC
Palamidas 2014 Short-term EC use only
Pearson 2012 Longitudinal study, but no data are reported for smoking cessation or reduction or for adverse events
Pokhrel 2013 Cross-sectional survey
Popova 2013 Cross-sectional survey
Schober 2014 Short-term EC use only
Siegel 2011 Retrospective survey of 222 EC users that responded to a survey sent to 5000 new users of the ’Blu’ EC. Likely
to be a self-selected sample
Tsikrika 2014 Short-term EC use only
Tzatzarakis 2013 Short-term EC use only
Vakali 2014 Short-term EC use only
Vansickel 2010 Short-term EC use only
Vansickel 2012 Short-term EC use only
Vansickel 2013 Short-term EC use only
Vardavas 2012 Short-term EC use only
Vickerman 2013 Cross-sectional survey
Wagener 2014 EC use for up to 1 week, but does not report on any adverse events
Walele 2016a RCT but follow-up too short
Walele 2016b RCT but follow-up too short
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Yan 2015 Ineligible study design
EC: electronic cigarette
Characteristics of ongoing studies [ordered by study ID]
Caponnetto 2014
Trial name or title Smoking cessation and reduction In schizophrenia (the SCARIS study)
Methods 3-arm prospective 12m randomized controlled trial investigating efficacy and safety of EC
Setting: psychiatric and smoking cessation centres, Italy
Recruitment: local newspapers and radio/television advertisements
Participants 153 participants, schizophrenic in stable phase of illness, smoked at least 10 cpd over previous 5 years, aged
18 - 65, in good general health, not currently attempting to quit smoke or wishing to do so in next 6m
Excluded if: use smokeless tobacco or NRT; pregnant or breastfeeding; current or recent (1 yr) history of drug
or alcohol abuse; other significant co-morbidities
Interventions 12-wk supply of:
1) EC, high nicotine (24 mg)
2) EC, no nicotine (0 mg, with tobacco aroma)
3) PAIPO nicotine-free inhalator
Outcomes Follow-up visits at 4, 8, 12, 24 and 52 wks
Outcome measures:
• Smoking cessation
• Smoking reduction (≥ 50% from baseline)
• Adverse events
• Quality of life
• Neurocognitive functioning
• Participant perceptions and satisfactions with products
Starting date September 2014
Contact information Pasquale Caponnetto, p.caponnetto@unict.it
Notes
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Trial name or title An open-label randomized pragmatic policy trial examining effectiveness of short-term use of Nicotine Re-
placement Therapy (NRT) vs short- or long-term use of NRT vs short- or long-term use of NRT or electronic
nicotine delivery systems for smoking cessation in cigarette smokers
Methods Phase 3 blinded RCT
Setting: Australia
Recruitment: commercial market research panel
Participants Target sample size: 1600
Current daily smokers (at least 6 cpd), can read and understand English, agree to try samples of nicotine
products, willing to complete surveys, 18 years or older
Excl. if currently treated for serious medical condition, pregnant or planning to become pregnant or breastfeed
in next 12m
Interventions a) Factsheet explaining relative harm of NRT compared to smoking, free sample of NRT, participant chooses
preferences, has free for 3 wks then offered at subsidised rate for further 6m
b) As (a) but with additional information provided
c) As (a) but additional information on electronic cigarettes and emphasis on cessation, and may select
electronic cigarettes as well as NRT
Outcomes 6 and 12m, self-report
Continuous abstinence, NRT and EC use, interest in quitting smoking and in quitting NRT, cigarette
consumption, product orders and use, quit attempts
Starting date Feb 2014
Contact information Coral Gartner, c.gartner@uq.edu.au
Notes
ISRCTN60477608
Trial name or title The efficacy of e-cigarettes compared with nicotine replacement therapy, when used within the UK stop
smoking service
Methods Multicentre pragmatic randomized controlled trial to examine the efficacy of e-cigarettes compared with
nicotine replacement therapy
Setting: UK stop-smoking service
Recruitment: participants attending UK stop-smoking service
Participants Target: 886 participants
Aged 18 or older, current smoker accessing stop-smoking service, able to read/write/understand English
Interventions Smokers who want help to quit smoking will be individually randomized to receive usual care (UC; a choice
of NRT combined with usual care behavioural support provided by a Stop Smoking Service) or EC with the
same behavioural support
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Outcomes Primary: CO-validated sustained abstinence rates at 52 wks post-TQD
Secondary: sustained abstinence at 4 and 24 wks, 7-day PP abstinence at 4, 24 and 52 wks, smoking reduction,
treatment ratings, adverse reactions, cost efficacy
Starting date April 2015
Contact information Anna Phillips, a.phillips@qmul.ac.uk
Notes
KCT0001277
Trial name or title Effect of an electronic cigarette for smoking reduction and cessation in Korean male smokers: a randomized,
controlled study
Methods Parallel single-blinded randomized controlled trial
Setting: Hospital, Korea
Recruitment: not specified
Participants Sample size not stated
Men, 18 or older, at least 10 cpd for past year, smoked for at least 3 years, motivated to quit or reduce cigarette
consumption. Excl. if history of serious disease or quit attempt in past 12m using NRT
Interventions 1) 50-min education sessions on smoking cessation and the use of smoking-cessation aids, instructed to visit
the medical office each month for evaluation and counselling by a health practitioner who was unaffiliated
with the study. Participants supplied with eGo-CTM EC from Ovale in 12-wk supply
2) As (1) but instead of EC given nicotine gum in 12-wk supply
Outcomes Primary: continuous abstinence at 12 and 24 wks
Secondary: 7-day PP abstinence at 12 and 24 wks, cpd, adverse events
Starting date May 2012
Contact information Yoo-Seok Cheong, Dankook University Hospital
Notes
Lopez 2016
Trial name or title Randomized controlled trial methods for novel tobacco products evaluation
Methods Randomized parallel-assignment double-blind trial
Setting: USA (2 sites)
Recruitment: message boards, radio, print, web-based advertising
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Participants Estimated enrolment: 520
Inclusion criteria: Age 21 - 65, smoke > 9 cpd for at least 1 yr, smoke regular filtered cigarettes or machine-
rolled cigarettes with filter, CO > 9 ppm, no ’serious quit attempt’ in past month, not planning to quit in
next 6m, interested in reducing cig consumption
Exclude if: pregnant or nursing, unstable or significant medical condition, use of non-cigarette nicotine in
past 7 days, uncontrolled mental illness or substance abuse
Interventions For 24 wks:
1) Cigarette substitute (plastic tube, does not provide drug delivery)
2) EC with no nicotine (EGO EC)
3) As (2) but 8 mg/ml nicotine
4) As (2) but 36 mg/ml nicotine
Outcomes Urinary NNAL and cotinine at 24 wks, biomarkers of oxidative stress, glutathione and 8 Isoprostanes
Starting date June 2015
Contact information Thomas Eissenberg, Virginia Commonwealth University
Notes
Lucchiari 2016
Trial name or title Benefits of tobacco free cigarette among heavy smokers undergoing a lung cancer screening program: a
randomized controlled study
Methods Randomized parallel-assignment double-blind trial
Setting: Early lung cancer detection programme (Cosmos II) at European Institute of Oncology
Recruitment: volunteers participating in screening programme
Participants Estimated enrolment: 210
Inclusion criteria: Smokers > 10 cpd for > 10 years, motivated to reduce smoking, not already in cessation
treatment
Exclusion criteria:
1. Symptomatic CVD
2. Symptomatic severe respiratory disease
3. Regular psychotropic medication use
4. Current or past history of alcohol abuse
5. Use of smokeless tobacco or NRT
6. Participation in another antismoking programme in the current year
Interventions All participants receive smoking cessation programme including a motivational interview and 3 months low-
intensity distance counselling
1) EC and activity tracker
2) Nicotine-free EC and activity tracker
3) Activity tracker
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Outcomes At 6 and 12m
Primary: pulmonary health
Secondary: psychological well-being, cpd, CO, daily activity, cough-related QoL, lifestyle
Starting date September 2014
Contact information Marianna Masiero, University of Milan
Notes
NCT01842828
Trial name or title Spain-UK-Czech E-cigarette Study (SUKCES)
Methods Randomized controlled trial, open-label pilot study
Setting: smoking cessation clinics in London, Madrid and Prague
Recuitment: via smoking cessation clinics
Participants 220 smokers seeking help to quit
Inclusion criteria: 18 or older,want help to quit
Exclusion criteria: pregnant or breastfeeding; enrolled in other research; currently using EC
Interventions 1) standard care plus 4 wks EC supply
2) standard care only
Outcomes • CO-validated continuous abstinence at 4 and 24 wks post-TQD
• Withdrawal symptoms at 1 and 4 wks post-TQD
• EC use
• EC taste and satisfaction compared to conventional cigarettes
• Adverse events
Starting date December 2013
Contact information Peter Hajek, p.hajek@qmul.ac.uk
Notes
NCT01989923
Trial name or title Smoking cessation in women with gynaecological conditions
Methods Randomized controlled trial, open-label feasibility study
Setting: hospital clinic, USA
Recruitment: in clinic
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Participants 30 women smokers with cervical dysplasia
Inclusion criteria: women smokers of at least 10 cpd over past year, diagnosis of cervical dysplasia, cervical
cancer, and lower genital tract dysplasia and cancer, aged 18 - 65
Exclusion criteria: previous diagnoses or treatment for cancer (except for non-melanoma skin cancer); stroke,
heart disease, heart attack, or irregular heart beat; pregnancy and lactation; plan to continue to use other
nicotine as well as study products; uncontrolled hypertension; using other stop-smoking medication; taking
prescription medicine for depression or asthma
Interventions 1) NRT patch (21 mg for first 3 wks, 14 mg for 2nd 3 wks) plus nicotine gum (2 mg) or lozenges (2 mg) for
6 wks
2) EC device (’Blu’ Cig) with refills to last 6 wks, number provided based on packs smoked a day x 1.5
Strength of EC reduced at 3 wks
Both groups receive identical cessation counselling
Outcomes At 6 and 12 wks via survey:
• Cpd
• PP abstinence at 7 and 30 days
• Smoking cessation
• Participants’ attitudes and beliefs towards treatments
• Adherence
Starting date June 2013
Contact information Laura A Beebe, laura-beebe@ouhsc.edu
Notes
NCT02004171
Trial name or title Electronic cigarettes or nicotine inhaler for smoking cessation
Methods Randomized controlled trial, open-label safety/efficacy study
Setting and recruitment not specified, USA
Participants 40 participants
Inclusion criteria: 18 - 60 years old, meet DSM-IV criteria for nicotine dependence, seeking treatment for
smoking cessation, smoking at least 15 cpd
Exclusion criteria: DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder; current
diagnosis of major depressive disorder; current diagnosis for other psychiatric disorders that may require
intervention over course of study; receiving treatment for nicotine dependence; pregnancy, lactation, or chance
of pregnancy; unstable medical condition; substance abuse diagnosis; use of cannabis or alcohol on more than
20 days in past 30 days; suicide risk
Interventions 4 wks:
1) ECs (2nd generation) with 24 mg nicotine cartridges, 1 - 2 cartridges daily
2) Nicotine inhaler with 10 mg cartridges, max 16 cartridges per day
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Outcomes Over 4 wks:
• cpd
• Withdrawal
• Benefits from smoking cessation (breathing, sense of taste and smell, physical fitness)
• Adverse events
• BMI
Starting date December 2013
Contact information Barney Vaughan, vaughan@nyspi.columbia.edu
Notes
NCT02029196
Trial name or title A study to evaluate the safety profile of an e-vapour product
Methods Randomized, open-label, multicentre trial
Participants 420 participants
Inclusion criteria: age 21 - 65 years, BMI 18 - 35 kg/m², established smokers (smoking 5 - 30 cpd for at least
1 year), not wanting to quit
Exclusion criteria: Use of NRT within 14 days, blood donation in previous 12 months, history of drug or
alcohol abuse, HIV or hepatitis positive, medically unwell, pregnant women
Interventions 12 wks:
Experimental: Participants who switch from using conventional cigarettes to using an e-vapour product (EVP)
. No further information available about this product
Control: Participants who continue smoking their usual conventional cigarette
Outcomes Over 12 wks:
Primary
• Vital signs
• ECG
• Lung function testing
• Clinical laboratory parameters
Secondary
• Craving and withdrawal symptoms
• Carboxyhaemoglobin
• High-density lipoprotein cholesterol
Starting date December 2013
Contact information Robert Turner, robert.turner˙cain@covance.com
Notes Sponsor: Imperial Tobacco Group PLC
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Trial name or title Smoking cessation and reduction in depression (SCARID)
Methods 3-arm prospective 12m randomized controlled trial investigating efficacy and safety of ECs
Participants 129 participants
Inclusion criteria: diagnosis of major depressive disorder (MDD) (according to DSM-5 criteria), smoke ≥ 10
cpd (for at least the past 5 years), age 18 - 65 years, in good general health, unwilling to quit smoking in the
next 30 days
Exclusion criteria: use of smokeless tobacco or NRT or other smoking cessation therapies, pregnancy or
breastfeeding, current or recent (< 1 yr) past history of alcohol or drug abuse or both, active suicidal in-
tention, other significant co-morbidities according to the Investigator’s clinical assessment (e.g. cancer, acute
myocardial infarction, unstable angina, severe cardiac arrhythmia, recent cerebrovascular incident, or severe
atherosclerosis)
Interventions 12-wk supply of:
1. EC 24 mg nicotine
2. EC 0 mg nicotine
3. Nicotine-free inhalator
Outcomes Follow-up visits at 4, 8, 12, 24 and 52 wks
Outcome measures:
• Smoking cessation
• Smoking reduction (≥ 50% from baseline)
• Adverse events
• Quality of life
• Neurocognitive functioning
• Participant perceptions and satisfactions with products
Starting date February 2015
Contact information Pasquale Caponnetto p.caponnetto@unict.it
Notes
NCT02143310
Trial name or title A study to evaluate the safety of electronic vapour products for 2 years
Methods Open-label, singe-group assignment, multicentre trial
Participants 420 participants
Inclusion criteria: participated in NCT02029196, age 21 - 65 years, BMI 18 - 35 kg/m², established smokers
(smoking 5 - 30 cpd for at least 1 year) not wanting to quit, willingness to use the electronic vapourizer
product for 2 years, no clinically significant abnormalities during the prior trial
Exclusion criteria: use of NRT within 14 days, blood donation in previous 12 months, history of drug or
alcohol abuse, HIV or hepatitis positive, medically unwell, pregnant women
Interventions Use of e-vapour product (EVP) for 2 years
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Outcomes Follow-up visits at 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months
Primary
• Change from baseline (BL) in blood pressure
• Change from BL in ECG
• Change from BL in lung function tests
• Change from BL in clinical laboratory parameters
Secondary
• Change from BL in craving and withdrawal symptoms
• Change from BL in biomarkers of exposure
• Change from BL in biomarkers of effect
Starting date May 2014
Contact information Robert Turner, robert.turner˙cain@covance.com
Notes
NCT02212041
Trial name or title Acceptability, patterns of use and safety of electronic cigarette in people with mental illness: a pilot study
Methods Single-group safety/efficacy study
Setting: London, UK, NHS mental health service trust
Recruitment: by invitation
Participants Estimated enrolment: 50
Inclusion criteria:
• smokers (≥ 5 cpd for > 1 yr and breath CO > 5 ppm)
• ages 18 - 65 years
• ICD-10 diagnosis of schizophreniform, schizophrenia, schizoaffective or bipolar disorder
Exclude if:
• used EC on > 2 occasions in the past 30 days;
• intend to quit smoking within the next 30 days;
• currently use medications that may reduce smoking (bupropion, varenicline, NRT, naltrexone,
buprenorphine, acamprosate, baclofen, clonidine, nortriptyline, anti-seizure medications, disulfiram);
• have unstable psychiatric conditions (hospitalization or change in dose of chronic medication in the
past 30 days);
• People with a serious medical condition including uncontrolled high blood pressure, something wrong
with their heart or blood vessels that occurred or got worse in the past 3 months (including fast or irregular
heart rhythm, angina, chest pain, had a heart attack or stroke);
• People who have ever had a serious stomach ulcer, and/or phaeochromocytoma (tumour of the adrenal
gland);
• People who in the last 3 months have had severe heartburn; or a stroke, or unstable kidney disease,
unstable liver disease, uncontrolled over-active thyroid gland;
• met DSM-IV criteria for drug dependence;
• have medical contraindications to nicotine, since nicotine intake may increase in this study;
• have past-month suicidal ideation or past-year suicide attempt;
• are pregnant, as determined through a pregnancy test.
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Interventions Free disposable ECs will be provided during 6 weeks to smokers with serious mental illness
Outcomes To 24 wks:
Primary: EC use, acceptability, respiratory symptoms, cotinine, nitrosamines, side effects of antipsychotics,
withdrawal symptoms, respiratory symptoms
Secondary: Predictors of EC use, psychiatric symptoms, physical symptoms
Starting date August 2014
Contact information Rocio Perez-Iglesias
Notes
NCT02261363
Trial name or title A mixed method EMA assessment of cognition and behavior among new ENDS users: an observational
cohort study
Methods Observational cohort study
Setting: community
Recruitment: volunteers
Participants Estimated enrolment: 120, 100 not intending to quit in next 30 days, 20 intending to quit
Selected inclusion criteria:
• aged 18 years or older
• daily smoker with at least 5 years of established daily smoking not taking smoking cessation
medications
• have not used an ENDS product (electronic cigarette) in the last 30 days
• be interested in trying an ENDS
• not have heart disease/uncontrolled blood pressure
• not have psychosis/suicidal thoughts
• not be currently enrolled in an alcohol treatment programme
Interventions Unclear whether participants will be encouraged to use EC or not
Outcomes Wks 1 - 3:
Primary: cigarette use, EC use
Secondary: motivation to quit
Starting date August 2014
Contact information Jennifer Pearson, American Legacy Foundation
Notes May not be eligible
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NCT02328794
Trial name or title Randomized clinical trial to reduce harm from tobacco
Methods Randomized parallel-assignment efficacy study, single-blind
Setting:
Recruitment:
Participants Target 6000 participants
Vitality beneficiaries, 18 or older, reported/tested positive for smoking, excluding participants who opt out
Interventions a) Standardized Vitality programme aimed at promoting tobacco cessation. This programme includes existing
employee benefits for quitting and the use of text/email messages to encourage tobacco cessation
b) as (a), plus free EC
c) as (b) plus access to free NRT, bupropion or varenicline
d) as (c) plus incentives across 6m for testing negative for tobacco use
e) as (c) plus provide money at start and lose money from this fund if they do not test negative across 6m
Outcomes Primary: verified abstinence at 6m
Secondary: abstinence at 1, 3 and 12m
Starting date January 2015
Contact information Scott Halpern, University of Pennsylvania
Notes
NCT02357173
Trial name or title A trial of e-cigarettes: natural uptake, patterns and impact of use
Methods Randomized parallel-assignment open-label trial
Participants Estimated enrolment 68
Inclusion criteria: age 18+, current smoker of at least 5 cpd for at least 1 year, at least some concern for health
effects of smoking
Exclude if:
• past 6 month use of EC
• ever purchase of EC
• recent history of cardiovascular distress (heart attack in past year; arrhythmia; uncontrolled
hypertension)
• recent history (past 3 months) of COPD, cancer (any non-dermatologic), or uncontrolled diabetes
mellitus
• pregnant or breastfeeding
• any major current psychiatric impairment, including current alcohol/drug abuse/dependence
• use of non-cigarette tobacco products (e.g. cigarillos) in the last 30 days
• current use of any smoking cessation medications
• current enrolment in a smoking cessation treatment study
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NCT02357173 (Continued)
Interventions 2/3 sample will be given EC (Blu) for a 3-wk period, to use as much or as little as they would like
1/3 sample will not receive EC to sample and will continue smoking their regular cigarettes as much or as
little as they would like
Outcomes At 3 months:
Primary: EC uptake and use, nicotine and cotinine, antecedents of EC use, use within smoking-restricted
areas
Secondary: smoking abstinence, smoking reduction, quit attempts
Starting date November 2014
Contact information Matthew Carpenter, Medical University of South Carolina
Notes
NCT02398487
Trial name or title Head-to-head comparison of personal vaporizers versus cigalike: prospective 6-month randomized control
design study (VAPECIG 2)
Methods Randomized parallel-assignment open-label trial
Setting: Italy, community
Participants Estimated enrolment: 200
Inclusion criteria: (smokers) in good general health committed to follow trial procedures
Exclude if:
• recent vaping history (stopped vaping < 3 months ago)
• use of any other form of non-combustible nicotine-containing products (chewable tobacco or nicotine
replacement therapy)
• symptomatic cardiovascular disease
• clinical history of asthma and COPD
• regular psychotropic medication use
• current or past history of alcohol abuse
• use of smokeless tobacco or nicotine replacement therapy
• pregnancy or breastfeeding.
Interventions Comparison between 2 types of EC; ’personal vaporizers’ and ’cigalike’
Outcomes 24 weeks: Smoking cessation, smoking reduction
Starting date October 2014
Contact information Riccardo Polosa
Notes
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NCT02417467
Trial name or title Evaluating the efficacy of e-cigarette use for smoking cessation (E3) Trial
Methods Randomized parallel-assignment double-blind trial
Setting: community, Canada
Recruitment: motivated volunteers
Participants Estimated enrolment: 486
Inclusion criteria:
• Active smoker, 10+ cpd, on average, for the past year;
• Aged 18 years or older;
• Motivated to quit according to the Motivation To Stop Scale (MTSS) (level 5 or higher).
Exclude if:
• Medical condition with a prognosis < 1 year;
• Current or recent cancer (< 1 year in remission);
• Pregnant or lactating women;
• Current or recent use (in the past 30 days) of any pharmacotherapy or behavioural therapy for
smoking cessation (e.g. Nicotine Replacement Therapies, bupropion, varenicline, or counselling);
• Any EC use (nicotine or non-nicotine) in the past 60 days, or ever use of any EC for > 7 days
consecutively;
• History of psychosis, schizophrenia, or bipolar disorder;
• < 1 month following a myocardial infarction, life-threatening arrhythmia, severe or worsening angina
pectoris, or cerebral vascular accident;
• Use of any illegal drugs in the past year (excluding marijuana);
• Planned use of tobacco products other than conventional cigarettes (e.g. cigarillos, cigars, snuff, shisha,
etc.) or marijuana during the study period.
Interventions Smoking cessation/relapse prevention counselling will be provided for all participants for a minimum of 30
minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at
week 4). Counselling will consist of a number of approaches, including reviewing smoking history, develop-
ment/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill
development
1) Nicotine-containing EC
2) Non-nicotine EC
3) Counselling only
Outcomes At 4, 12, 24 and 52 weeks:
Primary: PP abstinence
Secondary: multiple PP and continuous abstinence, change in cig consumption. Adverse events and dropouts
(at 12 weeks)
Starting date September 2016
Contact information Mark Eisenberg
Notes
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NCT02482233
Trial name or title A pilot randomized controlled clinical trial - “Electronic nicotine delivery device (e-cigarette) for perioperative
smoking cessation in veterans”
Methods Randomized parallel-assignment double-blind pilot trial
Setting: San Francisco Veterans Affairs Medical Center (SFVAMC), USA
Recruitment: veterans awaiting surgery
Participants Estimated enrolment: 30
Inclusion criteria:
• adults (age > 18)
• any gender
• scheduled to undergo elective surgery at the San Francisco Veterans Affairs Medical Center (SFVAMC)
• daily smoker, based on self-report of at least 2 cigarettes/day and having smoked in the last 7 days
• presenting to the anaesthesia preoperative (APO) clinic at least 3 days preoperatively
Exclude if:
• emergency surgery (booked < 24 hours preoperatively)
• consumers of non-cigarette forms of tobacco only (pipe, smokeless tobacco) or marijuana only
• already enrolled in a smoking cessation trial
• current smoking cessation pharmacotherapy
• daily user of EC
• previous adverse reaction to EC or transdermal nicotine
• poor proficiency of English language¸as indicated by need for an interpreter (including family
members) at the preadmission visit
• lacking capacity for consent (e.g. due to mental illness or dementia), as indicated by consent for
surgery and other medical procedures being obtained from a substitute decision maker
• pregnant or breastfeeding
• unstable cardiac condition (unstable angina, unstable arrhythmia)
Interventions All participants receive < 2 minutes brief advice, referral to California Smokers’ Helpline for proactive coun-
selling and self-help materials
1) 6-week supply of EC (NJOY)
2) Prescription for 6-week supply of NRT (Nicoderm CQ)
Outcomes Primary: smoking status on day of surgery (1 - 2 weeks post enrolment)
Secondary: smoking status at 8 weeks (confirmed by CO), 6 months, smoking reduction, EC use at 6 months,
dual use, cotinine, spirometry, postoperative complications, length of stay, adverse events, qualitative data
Starting date August 2015
Contact information Susan Lee
Notes
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NCT02487953
Trial name or title Electronic nicotine delivery systems (ENDS) as a smoking cessation treatment
Methods Randomized parallel-assignment double-blind trial
Setting: Smoking cessation research centre, USA
Recruitment: volunteers
Participants Estimated enrolment: 300
Inclusion criteria:
• Have no known serious medical conditions;
• Smoke an average of at least 10 cpd;
• Have an expired air CO reading of at least 15 ppm;
• Able to read and understand English;
• Express a desire to quit smoking in the next 30 days;
• Higher than median rating of enjoyment of airway sensory effects of inhaling smoke on Cigarette
Evaluation Questionnaire.
Exclusion criteria: multiple related to baseline health status
Interventions 1) Nicotine EC + nicotine patch
2) Nicotine EC + placebo patch
3) Placebo (non-nicotine) EC + nicotine patch
Nicotine patches will be provided for 2 weeks before TQD and 8 weeks after at full dose then dose weaning
for 4 weeks
EC will be provided for 1 week before TQD and 8 weeks after, then instructed to reduce
Outcomes Primary: abstinence at 4 - 8 weeks from TQD
Secondary: abstinence at 9 - 12 weeks, 13 - 16 weeks, 6 months
All abstinence validated by CO
Starting date January 2016
Contact information Al Salley: al.salley@duke.edu. PI Jed Rose
Notes
NCT02498145
Trial name or title Short term effects of electronic cigarettes in tobacco dependent adults
Methods Randomized parallel-assignment double-blind trial
Setting: community, USA
Recruitment: from cessation clinics and chest clinics
Participants Estimated enrolment: 40
Inclusion criteria: smoking 1 or more cpd
Exclude if:
• Unstable psychiatric conditions such as suicidal ideation, acute psychosis, severe alcohol dependence,
or dementia
• Unstable medical conditions requiring hospitalization
• Acute myocardial infarction or acute cerebrovascular accident within the past 30 days
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NCT02498145 (Continued)
• Unstable angina
• Current use of an electronic cigarette
Interventions All participants receive nicotine patch and intensive counselling
1) Nicotine EC
2) Non-nicotine EC
Outcomes At 8 wks and 6m:
Primary: change in daily smoking, change in CO
Secondary: change in lung function
Starting date October 2014
Contact information Stephen Baldassari
Notes
NCT02521662
Trial name or title A randomized-controlled clinical trial to evaluate the effectiveness and safety of combining nicotine patches
with e-cigarettes (with and without nicotine) plus behavioural support, on smoking abstinence
Methods Randomized parallel-assignment double-blind trial
Setting: community, USA
Recruitment: volunteers
Participants Estimated enrolment: 1809
Inclusion criteria:
• Smoke and want to quit in the next 3 months
• At least 18 years of age
• Are prepared to use a nicotine patch or a nicotine patch and EC together
Exclude if:
• pregnant women
• women who are breastfeeding
• current users of NRT products
• people currently enrolled in another smoking cessation programme or other cessation study
• people who have used an EC for more than 1 week in the last year for smoking cessation
• current users of non-nicotine-based cessation therapies (e.g. bupropion, clonidine, nortriptyline or
varenicline)
• people who have had a heart attack, stroke or severe angina within the previous 2 weeks
• people who self-report a history of severe allergies and/or poorly controlled asthma
Interventions All participants will receive withdrawal-oriented behavioural support for 6 weeks post-quit
1) Nicotine patch for 14 weeks including 2 week prequit
2) Nicotine patch and nicotine-free EC for 14 weeks
3) Nicotine patch and nicotine EC for 14 weeks
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NCT02521662 (Continued)
Outcomes Primary: Continuous abstinence at 6 months with CO validation
Secondary: Self-reported continuous abstinence, PP abstinence, number of cigs, smoking reduction, time
to relapse, withdrawal, self-efficacy, use of other cessation methods/products, compliance, dual use, serious
adverse events, opinions
Starting date March 2015
Contact information Natalie Walker
Notes
NCT02527980
Trial name or title E-cigarettes: dynamic patterns of use and health effects
Methods Prospective observational study
Setting: community, USA
Recruitment: Smokers and dual EC and cigarette users
Participants Estimated enrolment: 450
Inclusion criteria:
• ≥ 18 years old
• no plans to quit smoking and/or EC use in the next 30 days
• not currently taking smoking cessation medication
• not currently in treatment for psychosis or bipolar disorder
• participants must report either that they have: smoked at least 5 cpd for the past 6 months and not
used EC within the last 3 months (”exclusive smokers“) or used nicotine-containing EC at least once a week
for the past month and have smoked at least 5 cpd for the last 3 months (”dual users“).
Interventions ”We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively CCs (n
= 175) and dual users of e-cigs and CCs (n = 275)“
Outcomes ’We will use state-of-the-art ecological momentary assessments to determine:
1) dynamic patterns of e-cig and CC use and related outcomes (e.g. dependence, withdrawal symptoms, CC
quit attempts and quitting success);
2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics) variables
that covary meaningfully with e-cig and CC use and related outcomes;
3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g. reduced
pulmonary function).”
Starting date September 2015
Contact information PI Megan Piper
Notes
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NCT02590393
Trial name or title The role of nicotine and non-nicotine alkaloids in e-cigarette use and dependence
Methods Randomized parallel-assignment double-blind trial
Setting: Smoking research clinic, USA
Recruitment: volunteers
Participants Estimated enrolment: 375
Inclusion criteria:
• Have no known serious medical conditions;
• Are 18 - 65 years old;
• Smoke an average of at least 10 cpd;
• Have smoked at least 1 cumulative year;
• Have an expired air CO reading of at least 10 ppm;
• Are able to read and understand English.
Exclude if: multiple, related to baseline health status
Interventions 1) Switch to standard nicotine EC use for 8 wks
2) Switch to ECs with same nicotine but very low non-nicotine alkaloid levels
3) Switch to ECs with very low nicotine and non-nicotine alkaloids
Outcomes Primary: CO levels at 8 wks
Secondary: EC use, EC solution use, cig use, at 8 wks
Starting date May 2016
Contact information Jed Rose
Notes “This is not a smoking cessation study; smokers will not be asked to quit smoking, and e-cigarettes will not
be used as a medical device or therapy.”
NCT02628964
Trial name or title Assessing the use of electronic cigarettes (e-cigarettes) as a harm reduction strategy
Methods Randomized parallel-assignment double-blind trial
Setting: Community, USA
Recruitment: Volunteers
Participants Estimated enrolment: 100
Inclusion criteria:
Exclude if:
Interventions All participants will receive a 20 - 30-minute behavioural counselling consultation with a trained tobacco
counsellor. Counsellors will review each participant’s smoking pattern and offer tailored behavioural and
environmental change strategies including specific smoking reduction strategy options. Participants will be
given a supply of EC and followed for 3 weeks
1) Nicotine EC
2) Non-nicotine EC
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Outcomes Primary: cpd and reduction at 3 wks
Secondary: Adverse effects, use of other tobacco products, satisfaction, craving, withdrawal, up to 12 wks
Starting date May 2015
Contact information Donna Shelley
Notes
NCT02635620
Trial name or title Changes in lung function parameters, bronchial reactivity, state of health and smoking behaviour associated
with changing from conventional smoking to electronic cigarettes
Methods Prospective observational study
Setting: Community, Germany
Recruitment: Vape shops and smoking cessation clinics
Participants Estimated enrolment: 80
Inclusion criteria:
• smoking ≥ 5 years
• smoking ≥ 10 cpd
• no intention to stop smoking within the last 3 months
• using EC with nicotine
• no infection of airways at the time of measurements
• EC group: intending to use EC
• control group: smoking cessation in the framework of a clinical conducted programme
Exclude if:
Interventions Comparison between:
1) Smokers who intend to start EC use for the first time
2) Smokers who intend to quit smoking within a clinical conducted smoking cessation programme
Outcomes Primary: Lung function, QoL, respiratory tract inflammation
Starting date October 2015
Contact information Tobias Rüther
Notes
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NCT02648178
Trial name or title Evaluation of appeal and impact of e-cigarettes among chronic smokers with smoking-related cancers
Methods Randomized open-label study
Setting: Medical centre, USA
Recruitment: Patients with cancer
Participants Estimated enrolment
Inclusion criteria:
• Histological or cytological diagnosis of lung, head & neck, or bladder cancer within the past 5 years
• AJCC stages I - IV
• Daily smoking (at least 10 cpd for 10 years) and breath CO ≥ 9 ppm
• Does not wish to quit smoking now (anyone wishing to quit smoking will be referred for smoking
cessation counselling through the DHMC programme)
• May be receiving anti-cancer agents
• Age 18 or older
Exclude if:
• Cancer surgery planned in the next 9 wks
• Treatment with radiation planned for the next 9 wks
• Actively trying to quit smoking, or planning to in the next 30 days. (If a participant reports that they
plan to quit smoking in the next 30 days, we will call them after the 30 days to see if they are still trying to
quit)
• Any use of EC in the past 30 days
Interventions Participants with be supplied with 1 of 2 models of EC (HALO brand), 1 cigalike, the other a tank model
Outcomes Use of EC, CO, urine NNAL, at 3, 6, 9, 12 wks
Starting date January 2016
Contact information Katie H Rice. PI James Sargent
Notes
BMI: body mass index
CO: carbon monoxide
COPD: chronic obstructive pulmonary disease
cpd: cigarettes per day
CVD: cardiovascular disease
EC: electronic cigarette
ECG: electrocardiogram
NNAL: carcinogen found in tobacco smoke
NRT: nicotine replacement therapy
PP: point prevalence
QoL: quality of life
TQD: target quit date
wk: week
yr: year
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D A T A A N D A N A L Y S E S
Comparison 1. Smoking cessation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nicotine EC versus placebo EC 2 662 Risk Ratio (M-H, Fixed, 95% CI) 2.29 [1.05, 4.96]
2 Nicotine EC versus nicotine
replacement therapy
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Adverse Events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants
reporting adverse events:
Nicotine EC versus placebo EC
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Proportion of participants
reporting adverse events:
nicotine EC versus nicotine
replacement therapy
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
A D D I T I O N A L T A B L E S
Table 1. Summary of proportion of participants abstinent from smoking at follow-up: cohort studies
Study Smokers mo-
tivated or un-
motivated to
quit?
In-
tervention vs
relevant Con-
trol
% abstinent
Cohort studies 6-month 12-month 18-month 24-month Notes
Adriaens 2014
1
Unmotivated
to quit
Nicotine EC 19.6% (10/
51)
Data from 8
month follow-up
Al-Delaimy
2015
Not defined.
43% intended
to quit in next
6m
Had ever used
nicotine EC at
baseline
5% (12/236) Compared to 10.
5% in never users
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Table 1. Summary of proportion of participants abstinent from smoking at follow-up: cohort studies (Continued)
Borderud
2014
Motivated to
quit
Used EC in
past 30 days at
baseline
14.5% Average follow-up
10 months. Com-
pared to 30%
in non EC users.
Denominators for
both groups not
known, but ITT
analysis
Caponnetto
2013b
Unmotivated
to quit
Nicotine EC 14% (2/14)
Ely 2013 Motivated to
quit
Nicotine EC2 44% (21/48)
Manzoli
2015
Not defined Nicotine EC 16% (51/319) Compared to 15%
non-users at base-
line
Pacifici 2015 Unmotivated
to quit
Nicotine EC 53% (18/34)
Polosa 2011 Unmotivated
to quit
Nicotine EC 23% (9/40) 15% (6/40) 13% (5/40)
Polosa 2014b Unmotivated
to quit
Nicotine EC 36% (18/50)
Polosa 2015 Not defined Nicotine EC 42% (30/71) 41% (29/71)
Cohort studies not allowing inclusion of non-
responders
Brose 2015 Not
defined. 46%
attempted to
quit in past 1
yr
Daily EC
users at base-
line
8% (7/86) Compared to 9.
5% non-daily EC
users and 12.9%
non-users
Etter 2014 Not defined Daily EC
users at base-
line
46% (16/35) Response rate:
47% (367/773)
completed follow-
up survey
Grana 2014b Not defined Used
EC in the past
30 days (even
once) at base-
10% (9/88) Re-
sponse rate: 81%
completed follow-
up
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Table 1. Summary of proportion of participants abstinent from smoking at follow-up: cohort studies (Continued)
line Abtsinence rate
was 14% (119/
861) in non-EC
users
Choi 2014 Not defined UsedEC for≥
1 day in the
past 30 days at
baseline
11% Response rate: un-
known
Abstinence rate
was 17% in non-
EC users
Prochaska
20141
Not defined.
24% intended
to quit smok-
ing in next
month
EC use
at baseline via
open-ended
question
21% Fol-
low-up period un-
clear, 12m is esti-
mate. Denomina-
tor unclear. Com-
pared to 19% not
reporting EC use
1Technically an RCT but observational for purposes of EC analysis.
2All participants (N = 48) used an EC, but 16 also used bupropion and 2 used varenicline.
WH A T ’ S N E W
Last assessed as up-to-date: 14 January 2016.
Date Event Description
23 June 2016 New search has been performed Update search run January 2016, 11 new included studies
added. Reduction removed as outcome, now covered in
Harm Reduction review
23 June 2016 New citation required but conclusions have not changed 11 new included studies added; no changes to conclu-
sions.
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C O N T R I B U T I O N S O F A U T H O R S
All authors contributed to the writing of this review.
JHB, HM and LS extracted data, with discrepancies and disagreements referred to PH.
As principal investigator of one of the included trials, CB was not involved with data extraction or assessment of study quality.
D E C L A R A T I O N S O F I N T E R E S T
Within the last three years HM has received honoraria for speaking at research symposia and received benefits in kind and travel support
from, and has provided consultancy to, the manufacturers of smoking cessation medications.
Within the last three years PH has provided consultancy for and received research funding from GSK, Pfizer, Novartis and other
manufacturers of smoking cessation medications.
Two authors (HM, CB) have additional declarations:
CB and HM were investigators on a study of ECs from an EC manufacturer (Ruyan Group, Beijing and Hong Kong). Ruyan supplied
the ECs used in the trial and contracted with Health NZ Ltd. to undertake the study. Health New Zealand Ltd funded The University
of Auckland to conduct the trial, independently of Ruyan Group (Holdings) Ltd. The trial design conduct, analysis and interpretation
of results were conducted independently of the sponsors.
CB and HM were investigators on the ASCEND EC trial funded by the Health Research Council of New Zealand that used product
supplied at no charge from PGM international, a retailer of ECs.
JHB, RB and LS have no conflicts of interest to declare.
S O U R C E S O F S U P P O R T
Internal sources
• Queen Mary University of London, UK.
provides salary, office space and library resources for HM and PH
• The University of Auckland, New Zealand.
provides salary, office space and library resources for CB
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Originally, the protocol did not specify a minimum follow-up period for data on adverse events. TheMethods section has been changed
to clarify that we will exclude follow-up data at less than a week.
The original version of this review included reduction as a secondary outcome. The 2016 update removed reduction as an outcome,
to bring the review into line with other reviews of cessation treatments produced by the Cochrane Tobacco Addiction Group and to
prevent substantial overlap with the update of the group’s review of interventions for harm reduction (Stead 2007, update forthcoming).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Electronic Cigarettes [adverse effects; instrumentation]; Cohort Studies; Nicotine [administration & dosage]; Nicotinic Agonists
[administration & dosage]; Publication Bias; Randomized Controlled Trials as Topic; Smoking [epidemiology; ∗prevention & control];
Smoking Cessation [∗methods]; Tobacco Use Cessation Products
MeSH check words
Humans; Middle Aged
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